

1

2

3 **Order and disorder – an integrative structure of the full-**  
4 **length human growth hormone receptor**

5

6

7 *Noah Kassem<sup>1#</sup>, Raul Araya-Secchi<sup>2#</sup>, Katrine Bugge<sup>1</sup>, Abigail Barclay<sup>2</sup>, Helena*  
8 *Steinocher<sup>1</sup>, Adree Khondker<sup>3</sup>, Aneta J. Lenard<sup>1</sup>, Jochen Bürck<sup>4</sup>, Anne S. Ulrich<sup>4</sup>,*  
9 *Martin Cramer Pedersen<sup>2</sup>, Yong Wang<sup>1</sup>, Maikel C. Rheinstädter<sup>3</sup>, Per Amstrup*  
10 *Pedersen<sup>5</sup>, Kresten Lindorff-Larsen<sup>1</sup>, Lise Arleth<sup>2&</sup>, Birthe B. Kragelund<sup>1&</sup>*

11

12

13

14 <sup>1</sup> Structural Biology and NMR Laboratory, Department of Biology, University of  
15 Copenhagen, Ole Maaløes vej 5, 2200-Copenhagen N, Denmark

16 <sup>2</sup> X-ray and Neutron Science, The Niels Bohr Institute, University of Copenhagen,  
17 Denmark

18 <sup>3</sup> Department of Physics and Astronomy, McMaster University, Hamilton, ON, Canada

19 <sup>4</sup> Institute of Biological Interfaces (IBG-2), Karlsruhe Institute of Technology (KIT),  
20 POB 3640, 76021 Karlsruhe, Germany

21 <sup>5</sup> Department of Biology, University of Copenhagen, Universitetsparken 13, DK-2100  
22 Copenhagen

23

24

25 #contributed equally

26

27

28

29

30

31

32 **&Corresponding authors:** Birthe B. Kragelund, [bbk@bio.ku.dk](mailto:bbk@bio.ku.dk); Lise Arleth,  
33 [arleth@nbi.ku.dk](mailto:arleth@nbi.ku.dk)

34

35 **Keywords:** Cytokine receptor, IDP, integrative structural biology, NMR, XRD, SAXS,  
36 SANS, MD, OCD

37

38 **Running title:** Structure of the full-length human GHR

39

40 **ABSTRACT**

41

42 Despite the many physiological and pathophysiological functions of the human growth  
43 hormone receptor (hGHR), a detailed understanding of its *modus operandi* is hindered  
44 by the lack of structural information of the entire receptor at the molecular level. Due  
45 to its relatively small size (70 kDa) and large content of structural disorder (>50%), this  
46 membrane protein falls between the cracks of conventional high-resolution structural  
47 biology methods. Here, we study the structure of the full-length hGHR in nanodiscs  
48 with small angle-X-ray scattering (SAXS) as the foundation. We developed an  
49 approach in which we combined SAXS, X-ray diffraction and NMR spectroscopy  
50 obtained on the individual domains and integrated the data through molecular dynamics  
51 simulations to interpret SAXS data on the full-length hGHR in nanodiscs. The structure  
52 of the hGHR was determined in its monomeric state and provides the first experimental  
53 model of any full-length cytokine receptor in a lipid membrane. Combined, our results  
54 highlight that the three domains of the hGHR are free to reorient relative to each other,  
55 resulting in a broad structural ensemble. Our work exemplifies how integrating  
56 experimental data from several techniques computationally, may enable the  
57 characterization of otherwise inaccessible structures of membrane proteins with long  
58 disordered regions, a widespread phenomenon in biology. To understand orchestration  
59 of cellular signaling by disordered chains, the hGHR is archetypal and its structure  
60 emphasizes that we need to take a much broader, ensemble view on signaling.

61

62

## 63 INTRODUCTION

64 The human growth hormone receptor (hGHR) is ubiquitously expressed<sup>1</sup>, and is  
65 activated by human growth hormone (hGH), produced in the pituitary gland. hGHR is  
66 important for regulating growth at a cellular and systemic level<sup>1,2</sup>, and is involved in  
67 the regulation of hepatic metabolism, cardiac function, bone turnover and the immune  
68 system<sup>3</sup>. Besides direct promotion of growth<sup>4</sup>, its ligand hGH can also indirectly  
69 regulate growth by initiating the synthesis of insulin-like growth factor-I (IGF-I), an  
70 important factor in postnatal growth<sup>2,5,6</sup>. Excess hGH production and mutations in the  
71 hGHR gene manifest in different diseases including cancer<sup>7</sup> and growth deficiencies<sup>8-</sup>  
72 <sup>11</sup>, with associated cardiovascular, metabolic and respiratory difficulties<sup>8</sup>, and both  
73 hGH-based agonists and antagonists of the receptor exist as approved drugs<sup>12,13</sup>.

74

75 The hGHR is one of ~40 receptors belonging to the class 1 cytokine receptor family<sup>14</sup>.  
76 The family is topologically similar with a tripartite structure consisting of a folded  
77 extracellular domain (ECD), a single-pass transmembrane domain (TMD), and a  
78 disordered intracellular domain (ICD)<sup>14-16</sup>. A characteristic trait of these receptors is  
79 the lack of intrinsic kinase activity, with the ICD instead forming a binding platform  
80 for a variety of signaling kinases and regulatory proteins<sup>15,17,18</sup>, as well as of certain  
81 specific membrane lipids<sup>16</sup> (**Fig. 1A**). Within the ECD, the receptors share a  
82 characteristic cytokine receptor homology domain consisting of two fibronectin type  
83 III domains (D1, N-terminal and D2, C-terminal), each with a seven stranded  $\beta$ -  
84 sandwich structure. Two hallmark disulfide bonds and a conserved WSXWS motif (X  
85 is any amino acid)<sup>19,20</sup> located in D1 and D2, respectively, are suggested to be important  
86 for cell surface localization and discrimination between signaling pathways<sup>19,21</sup>. In  
87 hGHR, this motif is instead YGEFS<sup>17</sup>, but the reason for this variation has remained  
88 enigmatic. Beside hGHR, group 1 of the class 1 cytokine receptor also encompasses  
89 the prolactin receptor (PRLR) and the erythropoietin (EPO) receptor. This group is  
90 considered to be the most structurally simple with one cytokine receptor homology  
91 domain and ligand binding in a 2:1 complex<sup>17,18</sup>.

92

93 Receptor activation is achieved by hGH binding to hGHR via two asymmetric binding  
94 sites<sup>22</sup>, leading to structural rearrangements that are propagated through the TMD to the  
95 ICD<sup>23</sup>. A recent study found that when hGH binds to a pre-formed hGHR dimer,

96 structural rearrangements in the ECD leads to separation of the ICDs just below the  
97 TMD<sup>23</sup>. This leads to activation through cross-phosphorylation of the Janus kinases 2  
98 (JAK2) bound at the proline rich Box1-motif in the juxtamembrane region<sup>23</sup>.  
99 Furthermore, this study demonstrated that receptor dimerization in isolation is  
100 insufficient for receptor activation<sup>23</sup>. Nonetheless, while recent single-particle tracking  
101 studies suggested dimerization to depend on expression levels<sup>24</sup>, it is still debated to  
102 what extent the hGHR exists as pre-formed dimers *in vivo*<sup>25</sup>, or if the hGHR only  
103 dimerizes upon hGH binding<sup>26</sup>.

104

105 From the viewpoint of structural biology, the hGH/hGHR system has a high molecular  
106 complexity with ordered and disordered domains joined by a minimal membrane  
107 embedded part. Hence, structural characterization of this receptor has so far utilized a  
108 divide and conquer approach, where the domains have been studied in isolation. This  
109 includes the crystal structures of the ECD in the monomeric state<sup>25</sup>, in 1:1<sup>27</sup>- and 2:1<sup>22</sup>  
110 complexes with hGH, and of hGH alone<sup>28</sup>. Furthermore, structures of the dimeric state  
111 of the hGHR-TMD in detergent micelles have been solved by nuclear magnetic  
112 resonance (NMR)<sup>29</sup> spectroscopy, while the hGHR-ICD was shown by NMR to adopt  
113 a fully intrinsically disordered region (IDR)<sup>16</sup>. A recent approach that combined  
114 experimental data with computational efforts provided a model of the similar PRLR  
115 monomer built from integration of several individual sets of experimental data recorded  
116 on isolated domains<sup>30</sup>. This work provided the first view of a full-length class 1  
117 cytokine receptor. However, no structure or model based on data collected on an intact,  
118 full-length class I cytokine receptor exists, leaving a blind spot for how the domains  
119 effect each other and are spatially organized.

120

121 Even with the major advances in cryo-electron microscopy (EM)<sup>31</sup>, the full-length  
122 hGHR remains a challenge to structural biology. With 70 kDa, the receptor is a small  
123 target for cryo-EM, but adding to this, the fact that more than 50% of the protein is  
124 intrinsically disordered leaves only ~30 kDa visible. Likewise, the intrinsic disorder of  
125 the ICD also hampers crystallographic studies. Orthogonally, 70 kDa plus membrane  
126 mimetics makes up too large a target for NMR, where the combined molecular  
127 properties would lead to slow tumbling and severe line broadening. Hence, the hGHR  
128 appears to be an orphan to structural biology, along with a large group of other

129 membrane proteins with long, disordered regions, including most of the ~1400 human  
130 single pass membrane proteins<sup>32</sup>. Lower resolution techniques, such as solution small-  
131 angle X-ray- and neutron scattering (SAXS/SANS) offer important alternatives and  
132 provide information about the solution structure of a protein regardless of whether it is  
133 disordered or not. These methods become particularly strong in combination with  
134 experimental information from orthogonal techniques through computational  
135 modelling. In such situations, SAS data allow for refining a low-resolution structure of  
136 a protein, including membrane proteins<sup>33,34</sup>. Recent advances building on the use of  
137 nanodiscs<sup>35</sup>, have further proved the applicability of SAS in membrane protein  
138 structural biology when combined with computational modeling<sup>36,37</sup>. Remarkably  
139 however, no membrane protein with the degree of disorder seen in hGHR has  
140 previously been studied in a nanodisc or approached by SAS.

141


142 Here we applied an integrative approach to access the structure of the monomeric  
143 hGHR from SAXS data recorded on the full-length receptor in a nanodisc. The data  
144 were validated and interpreted by combining SAXS, NMR and X-ray diffraction (XRD)  
145 data obtained on the individual domains of hGHR through computational modeling.  
146 This has resulted in the first experimentally supported structure model based on studies  
147 of an intact, full-length, single-pass cytokine receptor in a lipid membrane; a topology  
148 which represents ~40 human cytokine receptors and many other membrane proteins.  
149 Our approach exemplifies that combining SAS and computational modeling could be  
150 the bridge required for accessing structural information on the ~1400 single-pass  
151 receptors in humans<sup>38</sup>.

152

## 153 **RESULTS**

154 To arrive at the final result of this work we took on a three-step approach. First, to aid  
155 the analysis of SAS data on the full-length hGHR and qualify the integrity of the  
156 methodology, several different biophysical data were acquired and analyzed on  
157 isolated, individual parts of the hGHR. Secondly, SAS data were acquired on the full-  
158 length hGHR in nanodiscs, expressed in yeast cells and carrying a C-terminal GFP-  
159 deca-histidine tag (GFP-H<sub>10</sub>). Finally, all the data were interpreted and integrated using  
160 molecular dynamics simulations.

161



162

163 **Figure 1. The hGHR has a dynamic ECD with a broad structural ensemble.** (A) A  
 164 schematic representation of homodimeric hGHR (blue) in the membrane in complex  
 165 with hGH (green). ECD, Extracellular domain; TMD, transmembrane domain and ICD,  
 166 intracellular domain. (B) SEC profiles of hGHR-ECD and hGH in 20 mM  
 167  $\text{Na}_2\text{HPO}_4/\text{NaH}_2\text{PO}_4$  (pH 7.4), 150 mM NaCl at ratios 1:0 (hGH:hGHR-ECD 1:0), 0:1  
 168 (hGH:hGHR-ECD 0:1), 1:2 (hGH:hGHR-ECD 1:2), 4:1 (hGH:hGHR-ECD 4:1).  
 169 Absorption was measured at 280 nm. (C) Concentration-normalized SAXS data from  
 170 hGHR-ECD (concentrations in legend) with the  $p(r)$  from the 3.5 mg/mL sample shown  
 171 as insert. (D) SAXS data from hGHR-ECD at 3.5 mg/ml (black dots) together with fits

172 of the theoretical scattering curves from a crystal structure of hGRH-ECD (blue, PDB  
173 3HHR), the same crystal structure with missing loops completed (purple), and the  
174 average (green), and reweighted average (red) of scattering curves of the 500 hGHR-  
175 ECD models with added N- and C-terminal tails. Residuals are plotted below. (E) An  
176 ensemble model of the hGHR-ECD with a representative reweighted sub-ensemble of  
177 100 models highlighting the N- (cyan) and C- (green) terminal dynamic tails.

178

179

### 180 ***The binding competent hGHR-ECD solution state ensemble contains disorder***

181 While crystal structures of an N- and C-terminal truncated version of the hGHR-ECD  
182 exist<sup>22,27,28</sup>, the complete hGHR-ECD has not previously been studied in solution.  
183 Therefore, to describe the ensemble of the full domain, we purified hGHR-ECD  
184 (residues 1-245, omitting the signal peptide) and hGH from expression in *E. coli*. Based  
185 on CD data, the hGH was folded with the expected amount of helicity (**Suppl. Fig. 1A**).  
186 The CD spectrum of hGHR-ECD had pronounced positive ellipticities around 230 nm  
187 stemming from aromatic exciton couplings, a trait of cytokine receptors<sup>39</sup>, and showed  
188 as well additional contributions from disorder at 200 nm (**Suppl. Fig. 1B**). The  
189 functionality of the hGHR-ECD was confirmed from its ability to form complexes as  
190 determined from  $K_{av}$  for hGH, and its 1:1 and 1:2 complexes with hGHR-ECD by  
191 analytical SECs (**Fig. 1B, Suppl. Fig S1C-D**). By varying the ratio of hGH and hGHR-  
192 ECD, we could isolate the 1:2 complex and the 1:1 complex (GH in 4 times excess),  
193 and obtain the mass of hGH, hGHR-ECD and the 1:1 and 1:2 complexes using the  
194 forward scattering from SAXS and their physical extension from the derived pair-  
195 distance distribution functions,  $p(r)$ s (**Suppl. Table S1, Suppl. Fig. S1E-G**). Finally,  
196 to understand the ensemble properties of the hGHR-ECD in solution and generate a  
197 model, we acquired SAXS data on free hGHR-ECD at varying concentrations. The  
198 concentration normalized SAXS data overlaid perfectly (**Fig. 1C**) showing no visible  
199 interaction effects. The derived  $p(r)$  (insert, **Fig. 1C**) was skewed with a broad  
200 maximum around 30 Å and a maximum length ( $D_{max}$ ) of ~100 Å, consistent with the  
201 hGHR-ECD having a non-globular shape. Comparison of the SAXS data to a  
202 theoretical scattering profile obtained from one of the structures of hGHR-ECD (PDB  
203 3HHR)<sup>22</sup> resulted in a poor fit (**Fig. 1D**, blue), possibly due to the absence of the N- (1-  
204 30) and C-terminal (231-245) tails, and two disordered loops (57-61; 74-77). Next we  
205 built a model of the hGHR-ECD where the missing loops were added. The calculated  
206 scattering profile of this model provided a slightly improved fit to the SAXS data



207 confirming that a substantial contribution to the scattering comes from disorder and  
208 conformational heterogeneity of the N- and C- terminal tails. Thus, an ensemble of  
209 5000 models of the full-length hGHR-ECD including the N- and C-terminal tails in  
210 random configurations was built. An average of the theoretical scattering intensities  
211 from these was obtained and fitted to the experimental SAXS data (**Fig. 1D**, green).  
212 This was further refined by reweighting the ensemble against the experimental data  
213 using the Bayesian Maximum Entropy (BME) approach<sup>41,42</sup>, which brought  $\chi^2$  from  
214 34.88 to 4.67 using effectively 27% of the models, and improving the quality of the fit  
215 even further (**Fig. 1D**, red). The  $R_g$  distributions of the models before and after  
216 reweighting are shown in **Suppl. Fig. S1H**. A sub-ensemble of 500 conformations  
217 representative of the reweighted ensemble, was generated for building the model of the  
218 full-length hGHR (see below). A total of 100 conformations of this sub-ensemble is  
219 shown in **Fig. 1E**, illustrating how the disordered regions contribute considerably to the  
220 space-filling properties of the hGHR-ECD.

221

222 ***The hGHR-TMD is organized parallel to the membrane normal in its monomeric***  
223 ***state***


224 Structures of hGHR-TMD were recently solved in dimeric states<sup>29</sup> in micelles of the  
225 detergent d<sub>38</sub>-dodecylphosphocholine (DPC). To describe the structure and the tilt-  
226 angle of the monomeric hGHR-TMD relative to the membrane, we designed this  
227 domain of hGHR with six- and five-residues overlap with hGHR-ECD and hGHR-ICD,  
228 respectively. The resulting 36-residue hGHR-TMD (F239-R274), including an N-  
229 terminal G-S, was produced with and without isotope-labeling by a fast-track  
230 production method for single-pass TMDs<sup>43</sup>. Subsequently, the peptides were  
231 reconstituted in either lipid bilayers (see below) or 1,2-dihexanoyl-sn-glycero-3-  
232 phosphocholine (DHPC) micelles, successfully used for structure determination of the  
233 closely related hPRLR-TMD<sup>30</sup>.

234

235 A schematic overview of the extent of the hGHR-TMD  $\alpha$ -helix determined by NMR  
236 spectroscopy and bioinformatics is shown in **Fig. 2A**. To compare the structural  
237 characteristics of this hGHR-TMD with the previously published structures<sup>29</sup>, we  
238 analyzed isotope-labeled hGHR-TMD in DHPC micelles by NMR and CD  
239 spectroscopy (**Fig. 2B** and **Suppl. Fig. S2A,B**). From MICS analysis<sup>44</sup> of NMR



240 backbone chemical shifts and from backbone amide  $R_2$  relaxation measurements we  
 241 observed that the hGHR-TMD populated a fully formed  $\alpha$ -helix in DHPC micelles from  
 242 W249-K271 (**Fig. 2B**). This is in agreement with the findings for hGHR-TMD dimers  
 243 in DPC micelles<sup>29</sup>, suggesting the length of the TMD  $\alpha$ -helix to be maintained across  
 244 different membrane mimetics. From the backbone chemical-shift-derived dihedral  
 245 angles, a low-resolution structure to be used for building the full-length hGHR model  
 246 (see below) was calculated by CYANA<sup>45</sup>, covering the experimentally verified helical  
 247 backbone from W249-K271 (**Fig. 2C**).



248

249 **Figure 2. Position and definition of the single-pass  $\alpha$ -helical TMD.** (A) A schematic  
 250 overview of the extent of the TMD  $\alpha$ -helix determined by NMR spectroscopy and  
 251 bioinformatic predictions. Alignment of the first three and the last residues of the TMD  
 252  $\alpha$ -helix as determined by NMR spectroscopy (black), TMHMM<sup>116</sup> (light blue),  
 253 Phobius<sup>117,118</sup> (red), METSAT-SVM<sup>119</sup> (purple), and Uniprot annotations<sup>120,121</sup> (green).  
 254 The grey cylinder represents the length of the hGHR-TMD  $\alpha$ -helix determined by NMR  
 255 spectroscopy with the sequence number of the first and last residue in the  $\alpha$ -helix. The

256 numbers to the left of the sequences are the number of residues predicted in the TMD.  
257 (B) Top: Statistical probability for  $\alpha$ -helical conformation as calculated by MICS<sup>44</sup>  
258 based on sequence and backbone chemical shifts of hGHR-TMD in DHPC micelles,  
259 plotted against residue number. Bottom:  $R_2$  relaxation rates of hGHR-TMD in DHPC  
260 micelles plotted against residue number. Red diamonds highlight missing data points  
261 due to insufficient data quality or prolines. (C) Model of the hGHR-TMD  $\alpha$ -helix. (D)  
262 Electron density profiles of lipid bilayers (POPC:POPS 3:1 mol%) with varying  
263 concentrations of hGHR-TMD (0.2 mol% and 2 mol%, respectively). (E) Difference  
264 Electron density profiles with a schematic of hGHR-TMD in an orientation best fitting  
265 to the data. (F) Illustration of membrane curvature due to monomer and dimer hGHR-  
266 TMD. (G) Top: Herman's orientation of membranes at varying concentrations of  
267 hGHR-TMD. Bottom: Lamellar spacing of membranes at varying concentrations of  
268 hGHR-TMD. \*: one-fold change and \*\*\*: three-fold change. (H) Top: OCD spectra of  
269 6  $\mu$ g hGHR-TMD in POPC, with L:P ratios varied from 1:40 to 1:200. Bottom: OCD  
270 spectra of 6  $\mu$ g hGHR-TMD in POPC, POPC:POPS (3:1) or DOPC at L:P ratio 50:1.  
271 The dashed data lines represent nonreliable data due to too high HT values.  
272

273 To support the modeling, we reconstituted the hGHR-TMD in a more native-like  
274 membrane system of stacked bilayers of 1-palmitoyl-2-oleoyl-sn-glycero-3-  
275 phosphocholine (POPC): 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS)  
276 (3:1 molar ratio) and investigated its structure and tilt-angle by XRD. The measured  
277 reflectivity Bragg-peaks allowed us to determine the electron density profiles,  $\rho(z)$ , of  
278 the different bilayer structures (**Fig. 2D**) and difference plots,  $\Delta\rho(z)$ , (**Fig 2E**) of the  
279 membranes with and without inserted hGHR-TMD helices. The electron density  
280 profiles contain information about the position in the membrane and tilt angle. The  
281 electron density of the helices was calculated based on their PDB structures (PDB  
282 5OEK; 5OHND;2N71)<sup>29,30</sup> for different tilt angles and fitted to the experimental  
283 densities<sup>46</sup>.

284 The oligomeric state of single-pass TMDs was manipulated through the  
285 detergent-to-protein or lipid-to-protein (L:P) ratio<sup>29,38</sup>. The XRD analysis showed that  
286 at monomer conditions for the hGHR-TMD (high L:P ratio of 500:1, **Fig. 2E top**), the  
287 helix remained parallel to the membrane normal (tilt-angle  $0\pm 2^\circ$ ) without effects on  
288 membrane thickness,  $d_z$ . At dimer conditions (low L:P ratio of 50:1) we found that the  
289 helix tilt angle changed to  $40\pm 2^\circ$  relative to the membrane normal, in accordance with  
290 the GHR-dimer structures<sup>29</sup> (**Fig. 2E bottom**). While the membrane flatness and  
291 intactness, as measured by Herman's orientation function  $H$ , was unaffected by the  
292 presence of monomers or dimers (**Fig. 2F, top**), the dimer induced some membrane  
293 compression giving rise to a slightly thinner bilayer with smaller lamellar spacing,  $d_z$ ,  
294 (**Fig. 2F, bottom**). An illustration of this behavior is shown in **Fig. 2G**.

295


296 To further support these observations, we employed oriented CD (OCD) spectroscopy  
297 with reconstitution of the hGHR-TMD in POPC, POPC:POPS (3:1) or 1,2-Dioleoyl-  
298 sn-glycero-3-phosphocholine (DOPC) multilamellar bilayers (**Fig. 2H** and **Suppl. Fig.**  
299 **S2C**). In OCD, the ellipticity of the negative band at 208 nm, which is parallel polarized  
300 to the helix axis, is strongly dependent on helix orientation, allowing distinction  
301 between a fully inserted state (I-state, parallel to membrane normal), a tilted state (T-  
302 state) or surface bound state (S-state, perpendicular to the membrane normal). At dimer  
303 conditions (L:P ratio of 50:1), the OCD spectra showed two negative bands at 208 nm  
304 and 222 nm and a positive band at 190 nm in all types of membranes tested (**Fig. 2H**),  
305 indicating successful reconstitution with formation of helical structure. Furthermore,  
306 the negative ellipticity at 208 nm was smaller compared to that at 222 nm,  
307 demonstrating the hGHR-TMD to be either in a T-state or in an equilibrium between  
308 an S-state and an I-state<sup>47</sup>. Increasing the L:P ratio decreased the negative band intensity  
309 at 208 nm, which even became positive at a L:P ratio of 200:1 (**Fig. 2H, top**). This  
310 indicated that at monomer conditions, the hGHR-TMD populated the more parallel I-  
311 state, fully supporting the results from XRD.

312

### 313 *A C-terminal GFP has no influence on the ICD ensemble*

314 For purification of the full-length hGHR, a C-terminal GFP-H<sub>10</sub>-tag had to be  
315 included<sup>48</sup>. To ensure that this did not introduce intra- or inter-molecular interactions  
316 interfering with the hGHR-ICD ensemble, we produced the hGHR-ICD (S270-P620)  
317 without and with GFP-H<sub>10</sub> (hGHR-ICD-GFP-H<sub>10</sub>). <sup>15</sup>N-HSQC spectra of these two  
318 proteins were almost identical (**Fig. 3A**), confirming an unperturbed ensemble of the  
319 ICD. We also compared SAXS data acquired on both, which revealed a large increase  
320 in the forward scattering in the presence of GFP (**Fig. 3B**), reflecting the increase of the  
321 molar mass from 38.6 kDa for hGHR-ICD to 68.0 kDa for hGHR-ICD-GFP-H<sub>10</sub>  
322 (**Suppl. Table 1**). The derived  $p(r)$  functions (**Fig. 3D**) showed an increased probability  
323 of short distances due to the folded GFP, but also a conserved  $D_{max}$  consistent with an  
324 overall unaffected ICD coil conformation. The addition of GFP did not give rise to a  
325 significant change in  $R_g$  (65 Å for both) (**Fig 3B**), whereas the hydrodynamic radius ( $R_h$ )  
326 obtained by NMR spectroscopy, increased from 44 Å to 51 Å (**Fig 3 C**). We note that  
327  $R_g/R_h$  of ~1.5 for the hGHR-ICD falls in the range typically observed for linear chains  
328 in random coil conformations<sup>49</sup> while the smaller ratio obtained for the hGHR-ICD-

329 GFP-H<sub>10</sub> is consistent with the hGHR-ICD-GFP-H<sub>10</sub> containing a larger fraction of  
 330 folded protein. These results taken together indicate that the C-terminal addition of  
 331 GFP-H<sub>10</sub> did not change the structural ensemble of hGHR-ICD.  
 332



333

334 **Figure 3. Properties of the hGHR-ICD ensemble.** A) <sup>1</sup>H-<sup>15</sup>N-HSQC spectra at 5 °C  
 335 of hGHR-ICD (black) and hGHR-ICD-GFP-H<sub>10</sub> (red) at 150 μM and 100 μM,  
 336 respectively. (B) Concentration normalized SAXS data from hGHR-ICD (black dots,  
 337 1.1 mg/mL) and hGHR-ICD-GFP-H<sub>10</sub> (red dots, 2.2 mg/mL). Fits to the data are shown  
 338 for a Gaussian random coil model (orange) and from averaged scattering profiles from  
 339 1000 conformations taken from the hGHR-ICD<sub>metaD\_pws10</sub> simulation (1/ns) (blue).  
 340 Residuals are plotted below. (C) *R<sub>H</sub>* of hGHR-ICD and hGHR-ICD-GFP-H<sub>10</sub>  
 341 determined from pulsed-field gradient NMR. Signal decays of hGHR-ICD (black) and  
 342 hGHR-ICD-GFP-H<sub>10</sub> (red) are shown as a function of gradient strength together with  
 343 the corresponding fits. (D) Concentration normalized *p(r)*'s derived from the above  
 344 SAXS data from hGHR-ICD (black) and hGHR-ICD-GFP-H<sub>10</sub> (red). An sub-ensemble  
 345 of 200 conformations representative of the hGHR-ICD<sub>metaD\_pws10</sub> simulation is shown  
 346 in the right side of the plot.

347

348

349 *Scaling of the protein-water interactions is required to simulate the ensemble*  
350 *properties of hGHR-ICD*

351 To aid interpretation of the data of the full-length hGHR, the ensemble properties of  
352 the hGHR-ICD were modelled based on the SAXS data following two approaches: i)  
353 through fitting of the data by the form factor for simple (non-self-avoiding) Gaussian  
354 random coils<sup>50,51</sup>, and ii) using coarse-grained molecular dynamics simulations (CG-  
355 MD) adapted to better represent the dynamics of intrinsically disordered proteins  
356 (IDPs) to obtain an ensemble of conformations that describe the experimental data.  
357 Approach i) provided an excellent fit to the full experimental SAXS  $q$ -range yielding  
358 an  $R_g$  of  $68 \pm 4$  Å (**Fig. 3B**, orange) with a  $\chi^2$  of 1.51. This showed the average  
359 conformation of the hGHR-ICD to be very well described by a simple random coil  
360 model, which implicitly assumes a scaling exponent,  $\nu=0.5$ . Using values empirically  
361 predicted for unfolded proteins or IDPs, or derived from computational analyses<sup>52-55</sup>  
362 using slightly different scaling exponents (0.588-0.602), similar  $R_g$  values of  $\sim 65$  Å  
363 were obtained (**Suppl. Table S2**). Hence, the values agree closely, and the effect of  
364 assuming a simple idealized Gaussian random coil model has a negligible effect on the  
365 resulting  $R_g$ .

366

367 Protein-protein interactions may be overestimated in the Martini forcefield translating  
368 into unrealistic compaction of disordered regions and inability to reproduce  
369 experimentally obtained values for  $R_g$  or  $R_h$ <sup>56,57</sup>. Recent reports investigating two three-  
370 domain protein connected by flexible linkers suggested that this could be overcome by  
371 increasing the strength of protein-water interactions<sup>58,59</sup>. In the case of hGHR with a  
372 long, disordered ICD, we performed unbiased and enhanced sampling MetaDynamics  
373 simulations, using the Martini 3 force field modified by increasing the strength of the  
374 protein-water interactions in the range 5-15%. Our goal was to search for a value that  
375 could provide an optimized description of the ensemble of GHR-ICD. Back-mapped  
376 atomistic conformations from these simulations were used to calculate their average  $R_g$   
377 and to obtain theoretical scattering intensities, which were then fitted to the SAXS data  
378 of hGHR-ICD (**Suppl. Fig. S3**). Our results indicate that an increase in the protein-  
379 water interaction strength of 10% produced optimal results (**Fig. 3B** and **Suppl. Fig.**  
380 **S3**). Thus, we settled on rescaling the protein-water interaction by 10% to obtain a

381 reliable conformational ensemble of the hGHR-ICD<sup>1</sup> and to be used in the simulation  
382 of the full-length hGHR-GFP system.

383

#### 384 ***Full-length hGHR reconstituted in nanodiscs forms monomers and dimers***

385 The intact hGHR tagged with GFP-His<sub>10</sub> (hGHR) was expressed in the *S. cerevisiae*  
386 strain PAP1500, purified, and reconstituted into POPC-loaded MSP1D1 nanodiscs as  
387 described in Kassem *et al.*<sup>48</sup>. We used the MSP1D1 nanodisc and POPC as they are  
388 currently the most applied and best characterized carrier system by SAXS and  
389 SANS<sup>60,61</sup>, making computation of the nanodisc embedded full-length structure of  
390 hGHR more reliable. In SEC, the hGHR in MSP1D1 eluted over a broad peak from 10-  
391 14 mL (**Fig. 4A**). This suggested that the hGHR was reconstituted in the discs  
392 potentially as both monomers and dimers, or as higher order oligomers. To quantify the  
393 number of hGHR per disc, we performed an SDS-PAGE analysis of hGHR and  
394 MSP1D1 standards along with hGHR-loaded MSP1D1 discs isolated from the SEC at  
395 different elution volumes (**Fig. 4B**). From gel quantifications of hGHR and MSP1D1  
396 we found that the ratio over the peak varied from ~2 hGHR per disc (F1) to ~1 hGHR  
397 per disc (F3). Since reconstitution was conducted with a 10-times excess of discs to  
398 hGHR to minimize the probability of capturing more than one hGHR pr. disc, we argue  
399 that the distribution across the peak likely represent the equilibrium between dimeric  
400 and monomeric hGHR. These results also suggested that the hGHR can form dimers in  
401 the absence of hGH as previously suggested<sup>23</sup>, most likely through the TMD  
402 region<sup>23,25,62</sup>.

403

#### 404 ***Number of lipids in the hGHR loaded MSP1D1 nanodiscs is as expected***


405 We used phosphorus analysis<sup>63</sup> performed on samples across the SEC peak (**Suppl.**  
406 **Fig. S4A**) to quantify the number of POPC lipids in the hGHR-nanodiscs. In the  
407 fractions with dimers (F1), the ratio between MSP1D1 nanodiscs and POPC was  
408 115±19 and in the fraction with monomers (F3), it was 122±17. The standard deviation  
409 is based on two repetitive measurements each on two separate samples. This is  
410 comparable to results obtained in other studies of POPC nanodiscs with an  $\alpha$ -helical  
411 membrane-anchored protein<sup>36</sup> and in good agreement with the values obtained for

---

<sup>1</sup> Of note, in these simulations, we did not consider the formation of transient secondary structures previously observed by NMR<sup>16</sup>. However, at the resolution provided by SAXS this is a reasonable approach, which was also applied in the modeling and simulation of the full-length hGHR.



412 nanodiscs solely filled with POPC (~110-130 POPC pr. nanodisc<sup>60</sup>). The number of  
 413 lipids was used as input for the modelling of the SAXS data of hGHR-containing  
 414 MSP1D1 nanodisc.  
 415



416

417 **Figure 4. Incorporation of hGHR into MSP1D1, functional and structural**  
 418 **analysis.** (A) SEC profile of hGHR-loaded MSP1D1. The areas highlighted in grey  
 419 indicate fractions (F1-F3) used for the SDS-PAGE analysis in (B). (B) SDS-PAGE  
 420 analysis of hGHR and MSP1D1 standards along with hGHR-loaded MSP1D1.



421 Fractions F1-F3 were taken from the indicated positions of the SEC purified hGHR-  
422 loaded MSP1D1 shown in (A). The illustration above the gel shows the stoichiometry  
423 of the hGHR-loaded MSP1D1. (C) MST determination of equilibrium binding  
424 constants for hGH to hGHR-loaded MSP1D1. The mean values and the standard  
425 deviation were obtained by fitting a 1:1 binding model (full line) as described in  
426 Materials and Methods. Concentration normalized (D) SAXS data and (E) SANS data  
427 of the nanodisc embedded hGHR corresponding to the highlighted SEC frames in  
428 (Suppl. Fig. S4C,D). (F) Concentration normalized SAXS data from the dimer (green)  
429 and the monomer (red) fractions with the corresponding  $p(r)$  functions in insert. (G)  
430 Concentration normalized SANS data from the dimer fraction with the  $p(r)$  in insert.  
431

### 432 ***hGHR is not N-glycosylated when produced in yeast***

433 The hGHR has five confirmed N-glycosylation sites at N28, N97, N138, N143 and  
434 N282<sup>64</sup>, whereas it is unknown if it is O-glycosylated. To assess if the recombinant  
435 hGHR from *S. cerevisiae* was N-glycosylated, the electrophoretic mobility before and  
436 after treatment with endoglycosidase H was evaluated (Suppl. Fig. S4B). No mobility  
437 change was observed, and the band sharpness was equally high before and after  
438 treatment, suggesting lack of N-glycosylations. This is in line with previous  
439 observations on other human membrane proteins produced in the same yeast expression  
440 system<sup>65</sup>. To determine if yeast-produced hGHR was O-glycosylated, we performed a  
441 western blot with horse radish peroxidase conjugated with Concanavalin A that binds  
442 to mannose residues in O-glycosylated proteins<sup>65</sup>. A faint band corresponding to hGHR  
443 was seen indicating minor O-glycosylation (Suppl. Fig. S4B). As a negative control,  
444 MSP1D1 purified from *E. coli* was not detected (Suppl. Fig. S4B).

445

### 446 ***Recombinant full-length hGHR reconstituted in nanodiscs is fully binding competent***

447 To ensure that full-length hGHR embedded in the MSP1D1 nanodisc was functional,  
448 we measured equilibrium binding constants for the interaction between hGH and  
449 hGHR(MSP1D1) by microscale thermophoresis. In these studies, a 20 nM solution of  
450 fluorescently labeled (NT-647-NHS) hGH was incubated with increasing  
451 concentrations of hGHR(MSP1D1) (23 pM - 750 nM) using unlabeled hGH as control.  
452 With this approach, the dissociation constant between hGH and hGHR(MSP1D1) was  
453 determined to  $K_d = 5 \pm 2$  nM (Fig. 4C). As another control, we previously showed that  
454 hGHR(MSP1D1) is unable to bind human prolactin<sup>32</sup>, which cannot activate hGHR *in*  
455 *vivo*<sup>66</sup>. The affinities of hGH for hGHR-ECD have previously been reported as 1.2 nM  
456 and 3.5 nM for the first and the second site of hGH, respectively<sup>67,68</sup>. Taking all this  
457 into consideration, we find that our data agree well with previous findings and conclude

458 that the nanodisc-reconstituted, yeast-produced full-length hGHR is fully binding  
459 competent.

460

461

#### 462 ***SEC-SAXS and SEC-SANS data of the full-length hGHR in nanodiscs***

463 Structural data of the reconstituted full-length hGHR in a POPC-loaded MSP1D1  
464 nanodisc was obtained from SEC-SAXS (**Fig. 4D**, **Suppl. Fig. S4C**) and SEC-SANS  
465 (**Fig. 4E**, **Suppl. Fig. S4D**) with  $p(r)$  functions in inserts to **Fig. 4D,E**. As was the case  
466 for the initial analysis, the SEC-elution profiles from the SEC-SAXS and SEC-SANS  
467 (**Suppl. Fig. S4C,D**) were both relatively broad and consistent with the underlying  
468 heterogeneity and systematic decrease of the particle size. Analysis of the data obtained  
469 over the SEC-SAXS and SEC-SANS elution peaks confirmed this picture, and SEC-  
470 SAXS showed a decreasing  $R_g$  from 120 Å to ~75 Å over the frames from 10-14 mL  
471 (**Suppl. Fig. 4C**). The SEC-SANS derived  $R_g$  (**Suppl. Fig. 4D**, frames from 10-14 mL)  
472 also varied over the peak, but generally less than in the SAXS experiment as a  
473 consequence of the different contrast situations in the two cases. The decrease in both  
474 the  $R_g$ , the low- $q$  scattering intensity and the development of the  $p(r)$ 's over the SEC  
475 peaks is fully consistent with the presence of discs containing first two and then one  
476 hGHR, respectively, as also supported by the initial analysis (**Fig. 4A,B**). However, in  
477 addition to dimerization, the large  $R_g$ -values obtained from the left side of the SEC peak  
478 could also be affected by an overlap with the void volume (at 8-10 mL). From the data  
479 corresponding to discs with one hGHR and two hGHRs and their corresponding  $p(r)$ s  
480 (**Figs. 4F,G** with SEC fractions indicated in **Suppl. Fig. 4C**), a  $D_{max}$  of ~200-250 Å  
481 was observed for monomeric hGHR in nanodiscs (SAXS only<sup>2</sup>). The dimeric fractions  
482 exhibited significantly larger  $D_{max}$  of ~350 Å in both SAXS and SANS. This larger size  
483 likely results from the larger extension of the two long uncorrelated ICDs. The shoulder  
484 around 0.1 Å<sup>-1</sup> of the SAXS data (**Fig. 4F**) is a typical signature of the lipid bilayer  
485 from the embedding nanodiscs<sup>36</sup>.

486 While the starting structure of a monomeric hGHR can be readily built from the  
487 chain connectivity, the structure of an hGHR dimer cannot, which complicates  
488 modeling of its structure. Further experimental complications arise both from the

---


<sup>2</sup> Due to the low signal at the right side of the SEC-SANS peak, the data from the monomeric fractions were too noisy to allow for a robust further analysis.

489 potential overlap with the void volume in the SEC-SAXS/SANS experiments and from  
490 possible structural heterogeneity. This may originate from a dynamic monomer-dimer  
491 equilibrium, but also from different dimers being present in the nanodisc; the  
492 biologically relevant down-down dimer conformation, a trapped up-down  
493 conformation, and even higher order structures. We therefore focused on the reliable  
494 SEC-SAXS data representing monomeric hGHR in a nanodisc and used these data to  
495 obtain the monomeric full-length hGHR structure embedded in a nanodisc bilayer.

496

### 497 *The structure of the monomeric full-length hGHR in a nanodisc*

498 We followed a two-stage approach to derive a model of the structure of monomeric  
499 hGHR in the MSP1D1 nanodisc. First, we built a semi-analytical model of the  
500 nanodisc-embedded full-length hGHR (including the GFP) to refine the nanodisc  
501 parameters and validate the overall structure of the complex. Second, we used the  
502 nanodisc model from this first analysis in combination with data from a 21  $\mu$ s CG-MD  
503 simulation of the hGHR embedded in a POPC bilayer. This provided an ensemble of  
504 conformations that could be back-mapped to all-atoms, and used to describe the SAXS  
505 data jointly with the refined nanodisc parameters.



506

507 **Figure 5. Model of the full-length hGHR in nanodiscs.** (A) Schematic representation  
508 of the semi-analytical Gaussian random coil (SA-GRC) model. (B) Fits of the SA-GRC  
509 (blue) to the SAXS data of nanodisc embedded hGHR (with GFP) (blue) and of the  
510 ensemble of 2000 conformations from the hGHR +POPC<sub>pws10</sub> simulation embedded in  
511 the nanodisc (gray) and their ensemble average (red). (C) Representative snapshot from  
512 the hGHR-GFP+POPC<sub>pws10</sub> simulation (*see methods*). POPC lipids shown as gray  
513 sticks, protein depicted in surface representation. Some lipids and all water and ions are  
514 omitted for clarity. (D) Probability density of the  $R_g$  of the ECD (orange), ICD (green),  
515 ICD-GFP (red) and full-length protein (blue) measured from the last 20  $\mu$ s of the  
516 hGHR-GFP+POPC<sub>pws10</sub> simulation.  
517

518 The semi-analytical mathematical model of the nanodisc embedded full-length hGHR  
519 (**Fig. 5A**, see details in *Materials and Methods*) was described through four scattering  
520 amplitude components arising from, respectively, the ECD-TMD, the ICD, the attached  
521 GFP and the surrounding nanodisc. The model was implemented through the WillItFit  
522 platform<sup>70</sup> and different computational approaches were applied for the different terms.  
523 In brief, the ECD-TMD, connected through a flexible linker, was represented as a rigid  
524 body through the atomic coordinates of one of the models produced with Rosetta (See  
525 *Materials and Methods*). The disordered ICD and its ensemble of conformations was  
526 modelled with a Gaussian random coil model parametrized by its  $R_g$ . The attached GFP  
527 was described through its atomic coordinates (PDB 1EMA) and allowed to take a  
528 random orientation in a certain “confusion volume” in extension of the disordered ICD.  
529 For the surrounding nanodisc we allowed, as in our previous work<sup>36,37,69</sup>, the lipid  
530 bilayer to take a slightly elliptical shape parametrized through its axis ratio to account  
531 for the combined effect of less than maximal lipid loading and shape fluctuations. We  
532 then constrained and reparametrized the underlying geometrical model into molecular  
533 parameters such as the number of POPC per disc and the POPC area per headgroup.  
534 The scattering intensity corresponding to the model was calculated and fitted on  
535 absolute scale. An excellent model fit to the experimental data ( $\chi^2=1.6$ , **Fig. 5B**, blue)  
536 was obtained using a nanodisc containing 122 POPC lipids each with an area per  
537 headgroup of 66  $\text{\AA}^2$ , an axis ratio of 1.5 of the elliptical bilayer and an  $R_g$  of the  
538 Gaussian random coil modelling the ICD of 76  $\text{\AA}$  (see full account of model fit  
539 parameters in **Suppl. Table S3**). The number of lipids per disc was kept fixed at the  
540 value obtained from the experimental phosphorous analysis (**Suppl. Fig. S4a**).  
541 Likewise, the axis ratio of 1.5 was fixed based on previous analyses<sup>60</sup>. We note that the  
542 resulting fitted POPC area per headgroup fall well within the standard disc parameters  
543 of POPC loaded MSP1D1 nanodiscs<sup>36,69</sup> and that the  $R_g$  of the attached ICD accords

544 with the value we determined for the isolated ICD. The analysis shows that the semi-  
545 analytical model provides an CG low-resolution description of the nanodisc embedded  
546 GHR and form a basis for a more detailed molecular description.

547  
548 In the next stage, a CG-representation of the system was built containing the full-length  
549 receptor (residues 1-620) plus GFP (hereafter jointly named hGHR) embedded in a  
550 POPC bilayer (**Fig. 5C**). This full-length hGHR model was simulated with Martini 3  
551 using the 10% increase in the strength of protein-water interactions found optimal for  
552 simulation of the hGHR-ICD. We simulated this system for 21  $\mu$ s and extracted 2000  
553 conformations of hGHR (one every 10 ns) from the last 20  $\mu$ s. These were back-mapped  
554 to all-atom representation, and one by one embedded in the analytical nanodisc model  
555 that had been optimized through the above described semi-analytical approach and  
556 following the *WillItFit*-based procedure previously described<sup>36,37,70</sup>. SAXS scattering  
557 curves were calculated from the obtained ensemble (**Fig 5B**, grey), averaged (**Fig 5B**,  
558 red). We note that the average MD-derived model, despite not being refined against the  
559 experimental data in this final step, provided a very good fit to the experimental data as  
560 shown in **Fig. 5B** (red) with  $\chi^2$  of 3.75. This confirms that the integrative approach with  
561 separate refinements of the individual domains is credible and provide a self-consistent  
562 and quantitatively correct description of the obtained data.

563  
564 Further analysis of the trajectory showed that the experimental  $R_g$ s obtained from the  
565 SAXS analyses of the individual parts of the protein were reproduced in the simulations  
566 which gave average  $R_g$ -values of  $63.3 \pm 1.2$  Å for hGHR-ICD,  $65.2 \pm 1.3$  Å for hGHR-  
567 ICD-GFP-H<sub>10</sub> and  $24.9 \pm 0.04$  Å for the hGHR-ECD (**Fig. 5D**). Measurement of the  
568 average helix tilt angle ( $15.2 \pm 0.2^\circ$ ) (see **Suppl. Fig. S5A**), shows that the TMD  
569 remains nearly parallel to the axis normal of the membrane plane) as suggested by the  
570 XRD and OCD results obtained on the isolated hGHR-TMD. The ICD remained  
571 disordered and for the most part avoiding the membrane. Long-lived contacts and  
572 penetration of the bilayer was observed only for the intracellular juxtamembrane region  
573 (Q272-M277) and the Box1 motif (L278-K287) of the ICD, as well as for some residues  
574 from the ECD-TMD linker (**Suppl. Fig. S5B**, insert), in line with previous reports<sup>16</sup>.  
575 Visual inspection of the trajectory (**Suppl. movie M1**) showed that the ECD-TMD  
576 linker remained flexible allowing the ECD to adopt a range of orientations while  
577 remaining mostly upright as shown by the angle between the principal axis of the D2



578 domain and the z-axis (average  $36.8 \pm 0.7^\circ$ , **Suppl. Fig. S5C**). We note that the D1  
579 domain remained far from the lipid surface. The N-terminal tail of the ECD remained  
580 disordered without long-lived contacts with the folded part of the ECD or the  
581 membrane.

582


583 In summary, the integrative model of the full-length monomeric hGHR in a nanodisc,  
584 containing almost equal amounts of structural order and disorder, fully captured the  
585 SAXS data recorded on the complex molecular system. Hence, the model provides the  
586 first molecular insight into the structure of an intact, full-length class 1 cytokine  
587 receptor in a lipid membrane carrier system.

588

## 589 **DISCUSSION**

590 Membrane proteins take on a variety of different topologies, sizes and functions and a  
591 large portions of membrane proteins exist in tripartite structures that require different  
592 handling schemes and methodological studies. Such complexities are further amplified  
593 for membrane proteins having large fractions of structural disorder<sup>32,71,72</sup>, which impose  
594 obstacles to classical structural biology. Thus, different topologies and order/disorder  
595 dispositions require different approaches, and one particular group of membrane  
596 proteins falls between the cracks by being too small and unstructured for cryo-EM, too  
597 large for NMR spectroscopy and too dynamic for X-ray crystallography. An important  
598 subgroup of these membrane proteins, which plays key biological roles, is the cytokine  
599 receptor family.

600



601

602 **Figure 6. The ensemble structure of membrane embedded full-length human**  
603 **GHR.** (A) Representative ensemble of conformations obtained from the last 20  $\mu$ s of  
604 the hGHR-GFP+POPC<sub>pws10</sub> simulation. Color scheme and representations as in Figure  
605 5C. (B) Examples of the multitude of domain orientations of hGHR in the membrane.  
606 In the first panel, the structures of hGH (PDB 3HHR\_A, orange) and of JAK2-FERM-  
607 SH2 (PDB 4Z32, red) are shown. Color scheme and representation of hGHR and POPC  
608 as in Figure 5C.  
609

610 In the present work, we examined the structure of an archetypal and particularly  
611 challenging membrane protein, the cytokine receptor hGHR, for which 50% of its chain  
612 is intrinsically disordered (**Fig. 6**). The structure of the monomeric hGHR revealed that  
613 when inserted in a bilayer mimetic, neither the ECD nor the long, disordered ICD  
614 engage in long-lived contacts with the membrane. This is remarkable, although it  
615 should be noted that the lipids used in the current study are not fully mimicking the  
616 complexity of native membranes lacking phosphoinositides or/and cholesterol, just as  
617 the proteoglycan layer on the extracellular side and the cytoskeleton on the inside is  
618 missing. We did, however, capture some lipid interactions by the intracellular  
619 juxtamembrane region (**Suppl. Fig. S5B**), which have been previously described<sup>16</sup>. It  
620 is possible that the native composition of the bilayer may influence the conformation  
621 of the receptor, but inherently there is no affinity for the POPC bilayer. Thus, the  
622 intracellular, disordered domain protrudes away from the bilayer and into the cytosol.  
623 Its average  $R_g$  of 65-70 Å corresponds to an average end-to-end distance of about twice  
624 this value. This defines its capture distance and the large search volume (**Fig. 6** and  
625 **Suppl. Fig. S5D**), which allows it to scout for and engage with kinases, phosphatases  
626 and regulatory proteins such as the signal transducer and activator of transcription  
627 (STAT)s, suppressors of cytokine signaling (SOCS)s and the cytoskeleton<sup>14</sup>.

628

629 A particular noteworthy observation from the structure of hGHR is the disordered, ~30  
630 residue N-terminal of the ECD, which has been neglected in all previous structural  
631 studies. The role of this N-terminal IDR in GHR function is unknown, but N-terminal  
632 IDRs are present in other family members, including the EPOR. An isoform of the GHR  
633 with a 22 residues deletion in the disordered N-tail (*d3*-GHR) shows altered ERK1/2  
634 signaling but unaltered STAT5 signaling, and *d3*-GHR individuals show an increased  
635 lifespan<sup>73</sup>. Thus, key functional relevance is coupled to the N-tail. A search in the  
636 eukaryotic linear motifs (ELM) database<sup>74</sup> suggests the presence of a  
637 glycosaminoglycan attachment site,  $\text{1FGFS}_4$ , in the tail. Of relevance to this, the



638 WSXWS motif, which in hGHR is YGEFS, constitutes a C-mannosylation site linking  
639 the C1 atom of the  $\alpha$ -mannose to the indole C2 atom of the tryptophan<sup>75,76</sup>. The  
640 WSXWS motifs has also been suggested to bind GAGs<sup>21</sup>, so it is possible that the  
641 disordered N-tail of hGHR play similar roles as the WSXWS motif, and we notice a  
642 degenerate motif of this kind, also in the N-tail, given by the sequence <sub>16</sub>WSLQS<sub>20</sub>.  
643 Nonetheless, the function of the disordered N-tail of hGHR remains unestablished.

644

645 The integrative nature of our approach to determine the structure of the hGHR required  
646 development and optimization of several protocols. This was particularly necessary  
647 during the modelling and fitting of the SAXS data based on the combined semi-  
648 analytical and experimentally driven molecular modelling approach to account for the  
649 structure and large flexibility of the hGHR. Key to the success was a scaling of the  
650 strength of the protein-water interaction in the CG molecular dynamics simulations of  
651 the ICD and full-length hGHR. This enabled reliable fits to the disordered chain in  
652 terms of  $R_g$ . On the semi-analytical modelling side, we have expanded our previous  
653 approaches to interpret scattering data from bare nanodiscs and rigid membrane  
654 proteins incorporated into these<sup>36,37,69</sup>, to now also allow for modelling membrane  
655 proteins with significant amounts of intrinsic structural disorder. We emphasize that  
656 even if the parameters of the GHR model are custom fitted to the hGHR system, the  
657 approach is fully generalizable and may be adapted to membrane proteins of similar  
658 topology provided that high quality SAS data are available. Thus, the use of this  
659 integrative semi-analytical and MD simulation-based approach suggests that SAS in  
660 combination with MD simulations is a useful way of retrieving structural models to  
661 provide structural insight into otherwise “method orphan” membrane proteins, in  
662 particular highlighting the interdomain orientations. This opens the door for more  
663 systematic investigations of for example single-pass transmembrane proteins in  
664 different environments, e.g. with respect to the lipid composition, the buffer  
665 environment or with binding partners to understand how these very dynamic membrane  
666 proteins transduce information across the membrane. This additionally includes other  
667 single-pass membrane proteins with similar complexity such as the cadherins and cell  
668 adhesion molecules (e.g. down syndrome cell adhesion molecule), but also membrane  
669 proteins with long disordered regions such as the solute carrier family 9, type II receptor  
670 serine/threonine family, and palmitoyl transferases<sup>48,77</sup>.

671

672 A key observation made possible from acquiring data on the full-length hGHR, is the  
673 lack of restriction on the relative orientation of the domains (**Fig. 6**). Not only is the  
674 ICD and the N-tail disordered, but the flexible linker joining the ECD and TMD  
675 combined with the lack of membrane association allow them to freely reorient relative  
676 to each other, at least in the free state (**Fig. 6**). Thus, in addition to structure, it becomes  
677 important to consider how the flexibility of the entire chain take on roles in signaling.  
678 From our studies we were not able to derive if correlated motions between the ECD  
679 and the ICD exist. However, once the hGH binds to the ECD, changes in conformation  
680 and flexibility may propagate along the chain reaching the ICD and bound protein  
681 partners, eliciting signaling. Similar suggestions were put forward based on data from  
682 solid-state NMR studies on the epidermal growth factor receptor, revealing increased  
683 dynamics in the bound state<sup>78</sup>. Since the JAK2 binding site only constitutes ~6% of the  
684 ICD, and the STAT5 docking sites are ~200-300 residues away from it<sup>79</sup>,  
685 conformational changes involving redistribution of the structural ensemble of the long,  
686 disordered region need to be achieved in a controlled manner. It is currently unclear  
687 how this is accomplished, but phosphorylations or binding to other proteins are likely  
688 to impact the ensemble, including the degree of compaction. Finally, the long ICD has  
689 a high content of short linear motifs (SLiMs), which are distributed along the chain in  
690 SLiM hotspots<sup>15</sup>, and the space occupied by the free ICD (**Suppl. Fig. S5E,F**) may  
691 therefore enable room for generation of larger, supramolecular signaling complexes  
692 constituted by many partners. So far, only binary complexes involving the ICD have  
693 been considered. With the presence of two disordered chains in a dimer, the occupied  
694 space of each ICD chain is reduced due to steric exclusion, which may result in different  
695 supra-molecular complexes compared to those involving the monomer. Thus,  
696 understanding the role of structural disorder in orchestrating cellular signaling by  
697 disorder remains enigmatic. With the first structure of a full-length membrane protein  
698 embedded in a realistic membrane scaffold and containing a large disordered chain at  
699 hand, the understanding of regulation of signaling by disordered chains, often present  
700 in higher order assemblies of several chains, now has a molecular platform from which  
701 new questions can be tackled.

702

703

704

## 705 **Acknowledgments**

706 This work has been supported by the Novo Nordisk Foundation Synergy programme  
707 (BBK, LA), and Challenge Program (REPIN, BBK), the Lundbeck Foundation (BBK)  
708 and the Lundbeck Foundation Initiative BRAINSTRUC (KLL, BBK, LA). The authors  
709 acknowledge the ILL, France, for the allocated SEC-SANS beam time as well as the  
710 European Synchrotron Radiation Facility (ESRF) and PETRAIII at the Deutsches  
711 Elektronen-Synchrotron (DESY), Germany for the allocated SAXS beamtime.  
712 Furthermore, we thank Signe A. Sjørup and Jacob Hertz Martinsen for skilled technical  
713 assistance, Nicolai Tidemand Johansen for help in relation to nanodisc preparations,  
714 SAXS and SANS measurements and data reduction. We also thank the D22 technicians  
715 Mark Jacques, Anne Martel, Lionel Porcar, the beamline scientists Marta Brennich and  
716 Petra Pernot at BM29 and beamline scientist Hayden Mertens at P12 for technical  
717 support during beamtimes, including pilot beamtimes.

718

## 719 **Data availability**

720 All data generated and analyzed in this study will be made available as source data  
721 upon publication of the manuscript. SAS data will be uploaded to the SASBDB data  
722 base. Representative subsections of the MD data will be made available on github  
723 (<https://github.com/Niels-Bohr-Institute-XNS-StructBiophys>) while the full sets will  
724 be made available upon request to the authors.

725

## 726 **Code availability**

727 All codes utilized in this study are available from the authors upon request. The  
728 implemented *WillItFit* routines are open source and will be made accessible as an  
729 update on the *WillItFit* repository at Sourceforge:

730 <https://sourceforge.net/projects/willitfit/>

731

## 732 **Author contribution**

733 N.K., R.A-S., K.B., M.R., P.A.P., L.A., B.B.K. designed the research. N.K., R.A-S.,  
734 K.B., A.B., H.S., A.K., A.J.L., J.B., and A.S.U. performed research and/or contributed  
735 new reagents. N.K., R.A-S., K.B., A.B., H.S., A.K., J.B., M.C.P., Y.W., M.C.R.,  
736 P.A.P., K.L-L., L.A., and B.B.K. analyzed data. N.K., R.A-S, K.B., L.A., and B.B.K.  
737 wrote the paper with input from all authors.

738

739 **Competing interests**

740 The authors declare no competing interests.

741

742

743

## 744 **MATERIALS AND METHODS**

### 745 *hGHR-ECD expression and purification*

746 The DNA sequence coding for hGHR-ECD (1-245, C242S, no signal peptide) in a  
747 pET11a was bought from Genscript and transformed into competent Rosetta2  
748 (DE3)pLysS cells. These were grown in 1 L LB medium with 3 % (v/v) ethanol,  
749 containing 100 ug/mL ampicillin and chloramphenicol to  $OD_{600} = 0.6-0.8$ , and induced  
750 by addition of 0.5 mM of IPTG for 4 h at 37°C and 160 RPM. The cells were harvested  
751 by centrifugation (5000 x g for 15 min) and resuspended in 1x PBS (140 mM NaCl, 2.7  
752 mM KCl, 10 mM  $Na_2H_2PO_4$ , 1.8 mM  $KH_2PO_4$ ), pH 7.4 containing 25 % (w/v) sucrose  
753 and 5 mM EDTA. The cells were lysed on ice by sonication using an UP400S ultrasonic  
754 Processor, 6x30s sonication followed by 30s rest at 50% amplitude. Following  
755 centrifugation (20,000 xg, 4°C) for 25 min, the pellet was resuspended in 1x PBS pH  
756 7.4, containing 25 % (w/v) sucrose and 5 mM EDTA, repeated three times in total. The  
757 pellet was solubilized in 500 mL 50 mM Tris-HCL pH 8.5, 10 mM beta-  
758 mercaptoethanol (bME), 6 M urea and heated for 5 min at 55 °C and left O/N with slow  
759 stirring, 4°C. The amount of hGHR-ECD was estimated on an SDS PAGE by  
760 comparing to the LMW and diluted to a concentration below 0.1 mg/mL in 50 mM  
761 Tris-HCL pH 8.5, 10 mM bME, 6 M urea. To refold, hGHR-ECD was dialyzed against  
762 4 L 150 mM NaCl, 50 mM Tris-HCL pH, 8.5, 10/1 mM cysteamine/cystamin at 4°C,  
763 12 kDa MW cut off until the urea concentration was below 0.1 M. Following  
764 centrifugation at 20,000 xg for 15 min, the sample was placed on ice and stirred slowly  
765 while ammonium sulphate was added to a final concentration of 75 % (w/v) and then  
766 left for two hrs. The solution was centrifuged at 12,000 xg at 4°C, 25 min, and the pellet  
767 dissolved in 100 mL miliQ water and left for 2 h, followed by dialysis against 30 mM  
768  $NH_4HCO_3$ , pH 8.0 overnight at 4°C. After centrifugation at 13,000 xg for 15 min, the  
769 supernatant was concentrated using a Millipore spinfilter (10 kDa cut-off), and applied  
770 to a Superdex 75 16/85 column (GE health care) at 4°C, 150 mM NaCl, 30 mM  
771  $NH_4HCO_3$ , pH 8.5. Selected fractions were reapplied to a Superdex 200 increase 10/300  
772 GL column in 20 mM  $Na_2H_2PO_4$ , pH 7.5, 150 mM NaCl, prior to SAXS measurements.

773

### 774 *hGHR-ICD expression and purification*

775 The coding region for hGHR-ICD (S270-P620) was cloned into a pGEX-4T-1 vector,  
776 containing an N-terminal GST-tag followed by thrombin cleavage site and transformed  
777 into BL21(DE3) cells. Expression was done in 1L Terrific Broth (TB) medium

778 containing 100 ug/mL ampicillin. At  $OD_{600} = 0.6-0.8$  cells were induced by 1 mM of  
779 IPTG for 4 h, at 37°C and 160 RPM. Cells were harvested by centrifugation and  
780 resuspended in 40 mL 1x PBS, pH 7.4, 0.1 % (v/v) Triton X-100 and a tablet complete  
781 EDTA-free protease inhibitor cocktail. The cells were lysed on ice by sonication using  
782 an UP400S ultrasonic Processor, 4 times 30s sonication followed by 30s rest at 100%  
783 amplitude. Following centrifugation (20,000  $\times g$ , 4°C) to remove cellular debris, the  
784 lysate was applied to a Glutathione Sepharose 4 Fast Flow column (GE health care) and  
785 incubated for 2 h at 25 °C. The column was washed with 50 mL 1x PBS, pH 7.4 and  
786 eluted 20 ml 50 mM Tris-HCl, 10 mM reduced glutathione, pH 7.4. The eluted solution  
787 was dialyzed against 1 L 20 mM Tris-HCl, 150 mM NaCl, pH 7.4 at 4 °C. The GST-  
788 tag was cleaved off by the addition of 20U thrombin /L culture, leaving residues GS in  
789 the N-terminal. The sample was then concentrated, 10 mM DTT added and heated to  
790 72°C for 5 min, incubated on ice, and centrifuged for 20,000  $\times g$  at 4°C for 10 min. A  
791 final purification on a Superdex 200 increase 10/300 GL column (GE Healthcare) in 20  
792 mM  $Na_2H_2PO_4$ , pH 7.5, 150 mM NaCl was done and selected fractions were used for  
793 SAXS measurements.

794

#### 795 *hGHR-ICD-GFP-H<sub>10</sub> expression and purification*

796 The coding region for hGHR-ICD (S270-P620) including an N-terminal methionine,  
797 C-terminal TEV cleavage (ENLYFQS) site followed by a yeast enhanced GFP<sup>80</sup> and  
798 10 histidines (hGHR-ICD-GFP-H<sub>10</sub>) in a pET-11a vector was bought from GeneScript.  
799 Expression was done in 1L Terrific Broth (TB) medium (for SAXS) and in <sup>15</sup>N-labeled  
800 minimal medium (22 mM  $KH_2PO_4$ , 62.5 mM  $NaH_2PO_4$ , 85.6 mM NaCl, 1 mM  $MgSO_4$ ,  
801 1 ml "trace element solution", 4 g glucose, 1.5 g  $NH_4Cl$  (<sup>15</sup>N labelled nitrogen)) (for  
802 NMR) containing 100 ug/mL ampicillin. At  $OD_{600} = 0.6-0.8$ , expression was induced  
803 by 1 mM of IPTG for 3 h, at 37°C and 160 RPM. Cells were harvested by centrifugation  
804 and resuspended in 40 mL 1x PBS, pH 7.4, and a tablet complete EDTA-free protease  
805 inhibitor cocktail. The cells were lysed on ice by sonication using an UP400S ultrasonic  
806 Processor, 4 times 30s sonication followed by 30s rest at 100% amplitude. Following  
807 centrifugation (20,000  $\times g$ , 4°C), the pellet containing hGHR-ICD-GFP-H<sub>10</sub> was  
808 solubilized by adding 40 mL 20 mM  $NaHCO_3$  pH 8.0, 150 mM NaCl and 8 M urea.  
809 Following centrifugation (20,000  $\times g$ , 4°C), the supernatant was refolded by dialysis in  
810 two steps. First by dialysis in 4 L 20 mM  $NaHCO_3$  pH 8.0, 150 mM NaCl, 4 M urea at  
811 4°C using 3 kDa molecular weight dialysis bag cut-off for 4 h, and then in 4 L 20 mM

812 NaHCO<sub>3</sub> pH 8.0, 150 mM NaCl at 4°C overnight. Following centrifugation (20,000 ×g,  
813 4°C), the supernatant was applied to a prepacked 5 mL Ni-resin column. The column  
814 was washed with 3 column volumes (CV) of 20 mM NaCHO<sub>3</sub> pH 8, 150 mM NaCl, 10  
815 mM imidazole and eluted using 20 mM NaCHO<sub>3</sub>, pH 8.0, 150 mM NaCl, 250 mM  
816 imidazole. Fractions containing hGHR-ICD-GFP-H<sub>10</sub> were concentrated and applied to  
817 a Superdex 200 16/60 increase column in 20 mM NaH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>H<sub>2</sub>PO<sub>4</sub>, pH 7.5, 150  
818 mM NaCl. Fractions containing hGHR-ICD-GFP-H<sub>10</sub> were analysed by SDS-PAGE  
819 and selected fractions were used for SAXS and NMR experiments.

820

### 821 *hGH purification*

822 hGH in a pJExpress414 was bought from ATUM, USA (formerly known as DNA2.0)  
823 and transformed into competent BL21 (DE3) cells. These were grown in 1L TB  
824 containing 100 ug/mL ampicillin to OD<sub>600</sub> = 0.6-0.8 and induced by addition of 1 mM  
825 of IPTG for 4 h, at 37°C and 160 RPM. Cells were harvested by centrifugation (5,000  
826 xg, at 4°C, 25 min) and resuspended in 50 mL 50 mM Tris, 0,5 mM EDTA, pH 8.0, 1  
827 mM PMSF. Cells were lysed on ice by sonication using an UP400S ultrasonic  
828 Processor, 5 times 30s sonication followed by 30s rest at 50% amplitude. Following  
829 centrifugation at 10,000 ×g, at 4°C, 15 min, the pellet was resuspended in 20 mL 10  
830 mM Tris, 1 mM EDTA, pH 8.0, 1 mM mM PMSF. The pellet was re-centrifuged two  
831 times, the supernatant discarded, and solubilized in 250 mL 5 M guanidinium chloride  
832 (GuHCl), 200 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub>, pH 7.0, 15 mM bME. The solution was heated  
833 for 10 min at 55 °C and stirred mildly for 2 h at room temperature. The solution was  
834 diluted in denaturation buffer (5 M GuHCl, 200 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub>, pH 7.0, 15  
835 mM bME to reach a hGH protein concentration below 0.1 mg/mL. The solution  
836 dialysed in a 5 L beaker, with a drain in the top, filled with 5M GuHCl, 200 mM  
837 Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub>, pH 7.0, 15 mM bME. A peristaltic pump was used to add refolding  
838 buffer (20 mM NH<sub>4</sub>HCO<sub>3</sub> pH 8.0, 200 mM NaCl) in the bottom of the beaker with a  
839 flowrate of 1.5 mL/min. After three days, when the GuHCl concentration was below  
840 1.5 M, the dialysis bags were transferred to a new 5 L beaker with 20 mM NH<sub>4</sub>HCO<sub>3</sub>  
841 pH 8.0, 200 mM NaCl, and dialysed three times until the concentration of GuHCl was  
842 below 0.1 M. Following centrifugation for 18000 ×g for 10 min, the supernatant was  
843 concentrated using a Millipore Pellicon module to approximately 30 mL. The solution  
844 was applied to a Superdex75 26/600 column in 20 mM NH<sub>4</sub>HCO<sub>3</sub>, 100 mM NaCl, pH  
845 8.0. Selected fractions were dialysed against 5 L 20 mM Tris pH 8.0 twice, and applied



846 to a HiTrap QFF 5mL. The sample was eluted in 20 mM Tris pH 8.0 by a salt gradient  
847 from 0-1M NaCl at a flow rate of 5 mL/min over 20 CV. Selected fractions were flash  
848 frozen in liquid nitrogen and left at -20 prior to use.

849

#### 850 *Analytical SEC*

851 Analytical SEC experiments of a set of samples with various ratios of hGH:hGHR-  
852 ECD were run on Superdex 200 increase 10/300 GL column in 20 mM  
853 Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 100 mM NaCl at room temperature with a flowrate of 0.5  
854 mL/min. Protein sample concentration were in the micromolar range but varied. The  
855 column was calibrated using conalbumin (75 kDa), ovalbumin (44 kDa), carbonic  
856 anhydrase (29 kDa), ribonuclease A (13.7 kDa), acetone and blue dextran and apparent  
857 partition coefficient,  $K_{AV}$ , was determined for all peaks.

858

#### 859 *Circular dichroism spectroscopy*

860 Far-UV CD spectra were recorded on 10  $\mu$ M hGHR-TMD in 2 mM DHPC, 5  $\mu$ M hGH  
861 and 5  $\mu$ M hGHR-ECD in 10 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> (pH 7.4). The spectra were  
862 recorded on a Jasco J-810 Spectropolarimeter in a 1 mm quartz glass Suprasil cuvette  
863 (Hellma) at 20°C. A total of 10 scans were accumulated from 260 nm to 190 nm for  
864 each sample and buffer background was recorded at identical setting and subtracted.  
865 For hGHR-TMD, the background included 2 mM DHPC. The scan mode was  
866 continuous with a speed of 10 nm/min and a data pitch of 0.1 nm. The spectra were  
867 processed and smoothened (means-movement method, convolution width 25) and  
868 converted into mean residue ellipticity values.

869

#### 870 *hGHR-TMD purification*

871 hGHR-TMD was expressed in *E. coli* and purified as previously described<sup>43</sup>.

872

#### 873 *Oriented circular dichroism*

874 hGHR-TMD was dried under a flow of N<sub>2</sub> and subsequently dissolved in MeOH:CHCl<sub>3</sub>  
875 (5:1) to reach a final stock solution of 0.4 mg/ml hGHR-TMD. To validate the  
876 concentration, 100  $\mu$ l of the stock solution was dried under N<sub>2</sub> flow and resuspended in  
877 100  $\mu$ l 50 mM SDS in PB buffer (pH 7.0) and the absorbance at 280 nm was measured.  
878 Lipid stock solutions of POPC, DOPC and POPC/POPS (3:1) were prepared in

879 MeOH:CHCl<sub>3</sub> (1:1) at 0.25 mg/ml and 5 mg/ml. The protein and lipid stock solutions  
880 were mixed in the following L:P ratios; 40:1, 50:1, 70:1, 100:1, 150:1 and 200:1. 6 µg  
881 protein was applied to a quartz glass with a Hamilton pipette for each experiment. The  
882 sample was spread over a fixed circular area on the glass and subsequently dried under  
883 vacuum for 3 h to remove the MeOH:CHCl<sub>3</sub>. The dried sample was mounted in a  
884 sample holder and was hydrated overnight in a chamber with a saturated K<sub>2</sub>SO<sub>4</sub> solution  
885 at 20 °C. Finally, the samples were loaded into a rotor in a Jasco J-810  
886 spectropolarimeter and spectra were recorded from 8 different angles; 0, 45, 90, 135,  
887 180, 225, 270 and 315°. Each spectrum was measured twice from 260 to 180 nm with  
888 a scanning speed of 20 nm/min, a data pitch of 0.1 and a response time of 8 s. The  
889 spectra were averaged and reference OCD spectra from samples with the same amount  
890 of lipid was subtracted. The OCD spectra were recorded from 8 different angles to even  
891 out linear dichroism<sup>47</sup> (Suppl. Fig. S2C). The spectra from different angles were  
892 averaged and background-subtracted and normalized to the intensity at 222 nm. High  
893 voltage effects prevented the measurement of higher L:P ratios.

894

#### 895 *X-Ray Diffraction*

896 Highly-oriented multi lamellar membranes were prepared on single-side polished  
897 silicon wafers. POPC (Avanti), POPS (Avanti), and 1,2-dimyristoyl-sn-glycero-3-  
898 phospho-L-serine (DMPS, Sigma) were mixed with hGHR-TMD at 2 and 20 mol%  
899 concentrations in 2,2,2-trifluoroethanol:chloroform (1:1, vol/vol) at a solution  
900 concentration of 18 mg/mL. The wafers were sonicated in 1,2-dichloromethane for  
901 30 min, and then rinsed with alternating methanol and 18.2 MΩ · cm water. The wafers  
902 were dried, and 75 µL of solution was deposited. After drying, the samples were placed  
903 in a vacuum for 24 h at 37 °C to allow for trace solvent evaporation and annealing.  
904 Samples were then hydrated in a closed chamber at 97% RH with a separate K<sub>2</sub>SO<sub>4</sub>  
905 saturated solution for 48 h prior to scanning.

906

907 XRD data was obtained using the Biological Large Angle Diffraction Experiment  
908 (BLADE) at McMaster University. BLADE uses a 9 kW (45 kV, 200 mA) CuKα  
909 rotating anode at a wavelength of 1.5418 Å using a Rigaku HyPix-3000 2D  
910 semiconductor detector with an area of 3000 mm<sup>2</sup> and 100 µm pixel size<sup>81</sup>. All samples  
911 were prepared and measured in replicates to check for consistency. Electron density  
912 profiles were determined from specular reflectivity, as previously described<sup>46</sup>. The

913 lamellar spacing,  $d_z$ , was determined from the spacing of the reflectivity Bragg peaks.  
914 Herman's orientation function was determined by integrating the intensity of the 3<sup>rd</sup>  
915 Bragg peak as function of the meridional angle  $\phi$  (the angle relative to the  $q_z$  axis), as  
916 described in<sup>82</sup>.

917

#### 918 *NMR spectroscopy*

919 NMR spectra were recorded on a 750 MHz (<sup>1</sup>H) Bruker AVANCE spectrometer  
920 equipped with a cryogenic probe. Unless otherwise specified, all NMR samples  
921 contained 10 % (v/v) D<sub>2</sub>O and 1 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS).  
922 Proton chemical shifts were referenced internally to DSS at 0.00 p.p.m., with  
923 heteronuclei referenced by relative gyromagnetic ratios. Free induction decays were  
924 transformed and visualized in NMRPipe<sup>83</sup> or Topspin (Bruker Biospin) and analysed  
925 using CcpNmr Analysis software<sup>84</sup>. For hGHR-TMD, all NMR spectra were recorded  
926 at 37 °C in 2 mM tris(2-carboxyethyl)phosphine (TCEP), 0.05% (v/v) NaN<sub>3</sub>, 50 mM  
927 NaCl and 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> (pH 7.4). The spectra for backbone assignments  
928 of hGHR-TMD (HNCO, HNCAHC, HNCA, HNCACB, CBCA(CO)NH, <sup>1</sup>H, <sup>15</sup>N-  
929 HSQC) were measured on 1 mM <sup>13</sup>C,<sup>15</sup>N-hGHR-TMD solubilized in 210 mM DHPC.  
930 Secondary structure content was evaluated from backbone chemical shifts using the  
931 motif identification from chemical shifts (MICS) programme<sup>44</sup>.  $R_2$  transverse relaxation  
932 rates of 0.5 mM <sup>15</sup>N-hGHR-TMD in 110 mM DHPC were determined from a series of  
933 <sup>1</sup>H,<sup>15</sup>N-HSQC spectra with varying relaxation delays between 10 and 250 ms and triple  
934 replica at 130 ms. The relaxation decays were fitted to single exponentials and  
935 relaxation times determined using CcpNmr Analysis software<sup>84</sup>. A low-resolution  
936 model of hGHR-TMD was calculated using CYANA<sup>45</sup> including only dihedral angles  
937 restraints from TALOS<sup>85</sup> using the backbone chemical shifts. Standard settings were  
938 used calculating 50 conformers with 4000 torsion angle dynamics steps. The 10 best  
939 conformers, with the lowest CYANA target function score was used for further  
940 modelling.

941

942 All NMR data of hGHR-ICD and hGHR-ICD-GFP-H<sub>10</sub> were acquired at 5°C to  
943 minimize amide exchange in 1 mM TCEP, 150 mM NaCl and 20 mM  
944 Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> (pH 7.4). <sup>1</sup>H,<sup>15</sup>N-HSQC spectra were acquired at concentrations of  
945 150 μM for <sup>15</sup>N-hGHR-ICD and 100 μM for <sup>15</sup>N-hGHR-ICD-GFP-H<sub>10</sub>. The  
946 hydrodynamic radii ( $R_H$ ) of hGHR-ICD and hGHR-ICD-GFP-H<sub>10</sub> were determined

947 from a series of  $^1\text{H}$ ,  $^{15}\text{N}$ -HSQC spectra with preceding pulse-field gradient stimulated-  
948 echo longitudinal encode–decode diffusion filter<sup>86</sup> and with the gradient strength  
949 increasing linearly from 0.963 to 47.2 G cm<sup>-1</sup>. To determine the diffusion coefficients  
950 ( $D$ ) the decay curves of the amide peaks were plotted against the gradient strength and  
951 fitted in Dynamics Center (Bruker) using  $I = I_0 \exp(-D_x^2 \gamma^2 \delta^2 (\Delta - \delta/3) \times 10^4)$ , in which  $I$   
952 is the intensity of the NMR signal at the respective gradient strength,  $I_0$  the intensity  
953 without applied gradient,  $x$  the gradient strength in G cm<sup>-1</sup>,  $\gamma = 26752$  rad Gs<sup>-1</sup>,  $\delta = 3$   
954 ms,  $\Delta = 250$  ms.  $R_H$  was calculated from the diffusion coefficient using the Stokes–  
955 Einstein relation,  $R_H = k_B T / (6\pi\eta D)$ , with  $\eta$  being the viscosity of water at 5°C.

956

### 957 *Production of full length hGHR*

958 See Kassem et al.<sup>48</sup> for expression, purification and reconstitution of hGHR in POPC-  
959 containing MSP1D1 nanodiscs.

960

### 961 *Phosphorus analysis*

962 The POPC:GHR ratio of the formed nanodiscs with hGHR inserted was determined by  
963 phosphorus analysis<sup>63</sup>. This was done by hydrolyzing POPC in H<sub>2</sub>SO<sub>4</sub> to release free  
964 phosphate (PO<sub>4</sub><sup>3-</sup>), which reacted with molybdate to produce a blue chromophore,  
965 absorbing at 812 nm. A series of phosphate standards from 0 to 80 nM Na<sub>2</sub>HPO<sub>4</sub> and  
966 hGHR in MSP1D1 at approximately 1 μM were prepared. Aliquots of 175 μL of each  
967 sample were transferred to glass tubes. HClO<sub>4</sub> was added (400 μL 72 % (v/v)) to each  
968 sample and the glass tubes were loosely closed using glass pearls. The samples were  
969 heated to 180 °C in a water bath in a fume hood for 1 h and then left at room temperature  
970 to cool for 30 min. 4 mL of 125 mM (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub> x 4 H<sub>2</sub>O was added to each sample  
971 and vortexed, followed by addition of 500 μL 10 % (w/w) ascorbic acid and vortexed  
972 again. Samples were then heated to 80 °C for 10 min in a water-bath and subsequently  
973 cooled in ice-water. Absorption was measured at 812 nm. A phosphate standard curve  
974 was generated, using the Na<sub>2</sub>HPO<sub>4</sub> standards, by linear regression. The linear equation  
975 was then used to determine nmol content of phosphate in the hGHR in MSP1D1  
976 samples. The ratio between POPC and hGHR(MSP1D1) was calculated from the ratios  
977 between their concentrations.

978

### 979 *Gel quantification of hGHR-loaded nanodiscs*

980 Standards of hGHR and MSP1D1 with a known absorption at 280 nM were prepared  
981 and loaded in different amounts of the same gel as well as three aliquots of hGHR-  
982 loaded nanodiscs taken from three different positions of the SEC-elution profile  
983 (fraction 1, 2 and 3). The gels were stained with Coomassie brilliant blue G-250 (Bio-  
984 Rad) and subsequently destained in 15 % (v/v) ethanol, 5 % (v/v) acetic acid and 5 %  
985 glycerol (v/v). Gel images were obtained on a LAS4000 imager (GE Healthcare, USA)  
986 and the images were quantified in ImageJ<sup>87</sup>. The intensities of the standards were fitted  
987 by linear regression and the amount of hGHR relative to MSP1D1 quantified  
988 accordingly.

989

### 990 *Microscale thermophoresis*

991 hGH was labelled with NT-647-NHS<sup>88</sup> using the Monolith NT<sup>TM</sup> Protein Labelling Kit  
992 RED-NHS (NanoTemper Technologies) for 1 h at room temperature with NT-647-  
993 NHS at a molar ratio of 1:3 in labelling buffer following the protocol. These conditions  
994 favour the modification of the N-terminal amino group. Free dye was separated from  
995 reacted dye using the provided desalting column. The ratio between fluorophore and  
996 protein was 0.2. The equilibrium binding between 20 nM NT-647-NHS labelled hGH  
997 to hGHR(MSP1D1) was calculated from the change in thermophoresis  $\Delta F_{norm} =$   
998  $\Delta F_{hot}/\Delta F_{cold}$  measured on a Monolith NT.115 (NanoTemper Technologies). For  
999 hGH<sub>G120R</sub> the raw fluorescence change was used to determine the binding affinity. A  
1000 two-fold dilution series of monomeric hGHR from 750 nM to 23 pM was prepared in  
1001 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> (pH 7.4), 100 mM NaCl and measured in triplicates.  
1002 Samples were loaded into Monolith NT.115 Premium Capillaries (NanoTemper  
1003 Technologies), and thermophoresis and raw fluorescence signals measured at 25 °C  
1004 with a light-emitting diode (LED) power of 80% and an infrared (IR) laser power of  
1005 100%. The dissociated constant  $K_D$  was obtained by fitting the data by:

$$1006 \quad Y = Y_0 + \frac{(Y_F - Y_0)}{2[P]_{total}} \times \left( K_d + [P]_{total} + X - \sqrt{(K_d + [P]_{total} + X)^2 - 4[P]_{total}X} \right)$$

1007 where  $Y$  is the measured fluorescence/MST,  $X$  is the ligand,  $[P]_{total}$  is the total  
1008 concentration of the protein,  $Y_F$  is the estimated end point of the titration and  $Y_0$  is the  
1009 start point.

1010

### 1011 *N-glycosylation removal by endoglycosidase H*

1012 1 µg purified full length hGHR was incubated with 500 units of Endo-H (New Biolabs,  
1013 USA) at 4 °C in 20 mM NaH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub> (pH 7.4), 150 mM NaCl and 5 % (v/v)  
1014 glycerol. The sample was separated and analysed on a 15 % SDS-PAGE gel and  
1015 visualized by in-gel fluorescence on a LAS 4000 Imager (GE Healthcare, USA).

1016

#### 1017 *Western blotting*

1018 hGHR was separated on a 15 % SDS-PAGE gel and blotted to a PDVF membrane as  
1019 described in Pedersen et al., 1996<sup>89</sup>. Horse radish peroxidase conjugated Concanavalin-  
1020 A (SigmaAldrich L6397) was used to identify O-glycosylations after western blotting.  
1021 Chemiluminescence was detected by using the immobilon western chemiluminescent  
1022 HRP substrate from Millipore ® and the LAS4000 imager (GE Healthcare, USA).

1023

#### 1024 *Small angle x-ray and neutron scattering*

1025 SAXS data on hGH, hGHR-ECD and the hGH:hGHR-hECD 1:1 and 1:2 complexes  
1026 were collected at the PETRA III, P12 beamline (DESY synchrotron, Hamburg)<sup>90</sup>,  
1027 following standard procedures and at 8°C. All samples were concentrated and run on a  
1028 Superdex 200 increase 10/300 GL in 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl  
1029 prior to measuring. The most concentrated top fractions were taken, except for 1:1  
1030 complex, where the fraction was taken to the right of the peak, to make sure the  
1031 hGH:hGHR-ECD 1:2 complex was absent in the sample. hGH was measured at 1.8  
1032 mg/mL, ECD at 3.5 mg/mL, hGH:hGHR-ECD 1:1 complex at 0.3 mg/mL and the  
1033 hGH:hGHR-ECD 1:2 complex at 1.3 mg/mL. The scattering curves each of which is  
1034 an average of 40 frames were recorded and the buffer was measured before and after  
1035 each sample. Processing and preliminary analysis of data was done using the ATSAS  
1036 package<sup>91</sup>. As a part of the process, buffer scattering curves before and after the sample  
1037 were averaged and subtracted from the scattering curve of the sample. The scattering  
1038 curves were scaled into units of 1/cm via the ATSAS package<sup>91</sup> and using a  
1039 measurement of water as secondary standard. The data was logarithmically re-binned.  
1040 For the full length hGHR in MSP1D1, in-line SEC-SAXS of the sample in 20 mM  
1041 Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl was performed at BM29 (ESRF, Grenoble)  
1042 equipped with a Superose 6 increase 10/300 GL (GE health care) running at a flow rate  
1043 of 0.75 mL/min. In-line SEC-SANS data on the full length hGHR in MSP1D1 was  
1044 recorded on the D22 small-angle scattering diffractometer at ILL, Grenoble, France.  
1045 The in-line SEC was performed using a the recently commissioned and described



1046 modular HPLC system (Serlabo) in 20 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl  
1047 on a Superose 6 increase 10/300 GL (GE health care)<sup>61,92</sup>. The flow rate was lowered  
1048 from the 0.75 mL/min used in the SEC-SAXS measurements to 0.05 ml/min when the  
1049 peak was reached in the lower intensity SANS to get as good counting statistics on the  
1050 individual frames as possible. Two settings were used, 11.2 and 2.0 m (with collimation  
1051 lengths of 11.2 and 2.8 m, respectively), giving a q-range between 0.0044–0.46 Å<sup>-1</sup>.  
1052 The intensities were binned into 30 s frames.

1053

#### 1054 *Modelling of the hGHR-ECD*

1055 To build a model of the full-length hGHR-ECD that covers the same sequence of the  
1056 construct used in the experimental procedures the following steps were performed: i)  
1057 An available structure of the GRH-ECD from the PDB was selected (chain C of 3HHR,  
1058 residues 32 to 236). ii) Missing loops on the structure (57-61 and 74-77) were  
1059 completed using the MODELLER<sup>93</sup> interface of CHIMERA<sup>94</sup>. iii) The missing N-  
1060 terminal (residues 1 to 31) and C-terminal (residues 237 to 245) tails were modelled as  
1061 ensembles in order to capture their flexibility in the fitting of SAXS data. The  
1062 ROSETTA<sup>95</sup> routine “Floppy tail”<sup>96,97</sup> was employed to generate 5000 conformations  
1063 of both tails.

1064

#### 1065 *Modelling of the hGHR ECD-TMD linker*

1066 The linker between the hGHR-ECD and hGHR-TMD (S237-W249) is not present in  
1067 the available structures of hGHR-ECD and its structure may play a relevant role in  
1068 determining the proper ECD-TMD orientation. Thus, this linker was modelled to  
1069 provide a starting conformation of the hECD-TMD part of hGHR for further use in the  
1070 modelling of the full-length hGHR structure.. To do this, the recently developed  
1071 mp\_domain\_assembly protocol<sup>98</sup> was implemented in Rosetta\_MP<sup>99</sup> was used. The  
1072 structure of the ECD used correspond to chain C of 3HHR with completed loops  
1073 (residues 32-236) and the TMD structure correspond to an NMR derived models  
1074 (residues 250-272). A total of 5000 models were built with the best 10 (according to  
1075 their Rosetta score) selected for further analysis, and the best ranked model used as a  
1076 rigid body in the semi-analytical models of hGHR in a nanodisc and as starting  
1077 conformation in the building of the full-length hGHR CG model (see below).

1078

#### 1079 *Structural model for the full length hGHR-GFP*



1080 A full-length model of intact hGHR with a GFP on its C-terminus was built using the  
1081 different pieces modelled separately. A representative conformation from the re-  
1082 weighted sub-ensemble of the full-length ECD (residues 1-237) was aligned to the best  
1083 model of the ECD-TMD to obtain a complete ECD-TMD structure (residues 1-272). A  
1084 representative structure of the ICD (residues 273-620) was taken from the back-mapped  
1085 conformation from the CG-MetaD- $R_g$  simulation with 10% increase in the protein-  
1086 water interaction strength as described in *Results*. Rotations of the peptide bond  
1087 between residues 273-274 had to be adjusted to allow the correct orientation of the ICD  
1088 with respect to the TMD and the membrane plane. EGFP (PDB 1EMA) was added at  
1089 residue 620. The all-atom model was used to build a CG system using the Martini  
1090 Maker module<sup>100</sup> of CHARMM-GUI<sup>101</sup> to obtain a system of protein + POPC + water  
1091 + 150 mM NaCl for the martini 2 forcefield. The topology was later adapted to open  
1092 beta version of martini 3 (m3.b3.2)<sup>102</sup>. The final system contains 453662 beads and has  
1093 a size of 361x361x406 Å<sup>3</sup>.

1094

#### 1095 *Coarse grained MD simulations*

1096 All MD simulations were performed using Gromacs 2016 and 2018<sup>103</sup> using the open  
1097 beta version of the Martini 3 (3.b3.2) force field<sup>102,104,105</sup> that was modified in order to  
1098 avoid excessive compaction of the disordered regions. To find the optimal factor by  
1099 which an increase in the protein water-interactions better reproduces the  $R_g$  of the  
1100 hGHR-ICD, two sets of simulations were performed in which different values of the  
1101 protein-water interaction strengths ranging between 5% to 15% were used. Unbiased  
1102 simulations were performed with a 5%, 6%, 8% and 10% increase, while metadynamics  
1103 simulations (see below) were performed with a 10%, 11%, 12%, 13%, 14% and 15%  
1104 increase. Based on the best reproduction of  $R_g$  (see **Fig. S3**) we chose a 10% increase  
1105 in interaction strength and used this also for the simulation of the hGHR-GFP+POPC  
1106 system. Simulation parameters were chosen following the recommendations in<sup>106</sup>.  
1107 Briefly, the Verlet cut-off scheme was considering a buffer tolerance of 0.005 kJ/(mol  
1108 ps atom) The reaction-field method was used for Coulomb interactions with a cut-off  
1109 of 11 Å and a dielectric constant of  $\epsilon_r = 15$  for water. For van der Waals interactions  
1110 the cut-off scheme with a cut-off of 11 Å was used. The velocity rescaling thermostat  
1111 was employed with a reference temperature of  $T = 300$  K and 310 K for the hGHR-  
1112 ICD and hGHR-GFP+POPC simulations respectively, with a coupling constant of  $\tau_T =$   
1113 1 ps<sup>107</sup> in all cases. For the equilibrations, the Berendsen barostat was employed ( $p = 1$

1114 bar,  $\tau p = 3$  ps), whereas the production runs were performed with a Parrinello-Rahman  
1115 barostat ( $p = 1$  bar,  $\tau p = 12$  ps)<sup>108</sup>. A semi-isotropic pressure coupling was used for the  
1116 hGHR system embedded on a lipid bilayer. For all systems an initial round of  
1117 equilibrations with decreasing constraints applied to the protein beads (hGHR-ICD)  
1118 and protein beads and lipid beads (hGHR-GFP) was performed.

1119 Sampling of the hGHR-ICD simulations with an increase in the protein-water  
1120 interactions of 10%, 11%, 12%, 13%, 14% and 15% was enhanced using a well-  
1121 tempered metadynamics<sup>109</sup> protocol applied with PLUMED 2.5<sup>110</sup>. The  $R_g$  of the protein  
1122 was used as collective variable (CV) within the boundaries of 30 to 110 Å. The  
1123 metadynamics parameters used are: a bias factor of 50, gaussian height of 4.2 kJ/mol  
1124 and collective variable space Gaussian widths equal to 0.3.

1125 Analysis of the MD trajectories was performed using plugins and analysis tools  
1126 implemented in VMD<sup>111</sup>, GROMACS and PLUMED together with in-house prepared  
1127 tcl and python scripts. All molecular renderings were done with VMD.

1128

#### 1129 *Fitting of the SAXS data of the hGHR-ECD and hGHR-ICD by the MD models*

1130 Similar protocols were utilized to fit the SAXS data of the hGHR-ECD and hGHR-ICD  
1131 with the conformations obtained from the modelling of hGHR-ECD and MD  
1132 simulations of hGHR-ICD, respectively: i) For the hGHR-ECD the SAXS profile of  
1133 each conformation was directly calculated and fitted to the SAXS data using Pepsi-  
1134 SAXS<sup>112</sup> with all parameters free. For the conformations obtained from the different  
1135 hGHR-ICD simulations, an initial round of back-mapping was performed to go from a  
1136 coarse-grained to all-atoms as described in<sup>58</sup>, before calculating and fitting its SAXS  
1137 profile with Pepsi-SAXS. ii) From the fits, the average value of the hydration shell  
1138 contrast was calculated (hGHR-ECD = 7.4%; hGHR-ICD = 4%) and used as a fixed  
1139 parameter in a second round of fitting. iii) The average scattering profile of the  
1140 ensemble was calculated and compared to the data. iv) In the case of hGHR-ECD, the  
1141 BME<sup>41,42</sup> procedure, designed to integrate ensembles of molecular models (and  
1142 simulations) with experiments was used to reweight the ensemble against the  
1143 experimental data and refine the fitting. From the reweighted ensemble a representative  
1144 sub-ensemble of 500 conformations was obtained

1145

#### 1146 *Semi-analytical model for the ND embedded hGHR-GFP*

1147 To generate the semi-analytical model for the full-length hGHR, a combination of  
1148 analytical approaches to describe the nanodisc and the hGHR-ICD, and rigid body  
1149 modelling for the ECD-TMD and GFP was implemented the *WillItFit*<sup>70</sup> framework.  
1150 The mathematical model for hGHR in nanodiscs, illustrated in Fig. 5A, is composed by  
1151 four distinct amplitude components arising from the ECD-TMD, the ICD, the attached  
1152 GFP and the surrounding nanodisc. The final expression for the total scattering intensity  
1153 was calculated on absolute scale as the scattering amplitude squared:

$$1154 \quad I(q) = n \cdot \langle |A_{ECD-TMD}(\vec{q}) + A_{ICD}(\vec{q}) + A_{ICD-GFP}(\vec{q}) + A_{ND}(\vec{q})|^2 \rangle_{\Omega}$$

1155 where  $\langle \dots \rangle_{\Omega}$  denote the orientational average,  $|\dots|$  denote the complex norm,  $n$  is the  
1156 number-density of particles and  $A(\vec{q})$  is the scattering amplitude of each component for  
1157 a single particle. Subscript *ECD-TMD* refers to the hGHR-ECD with transmembrane  
1158 domain, *ICD* refers to the intrinsically disordered intracellular domain and *ICD-GFP*  
1159 refers to the GFP fused to the ICD and *ND* refers to the POPC loaded nanodisc. For  
1160 each amplitude term,  $A(\vec{q})$ , we furthermore have that  $A(\vec{q}) = \Delta\rho \cdot V \cdot F(\vec{q})$ , where  $\Delta\rho$   
1161 is the average excess scattering length density,  $V$  is the volume and  $F(\vec{q})$  is the  
1162 normalized form factor amplitude for the relevant component. The model for  $A_{ND}(\vec{q})$   
1163 is the same as we have described previously<sup>69</sup>: A stack of five elliptical cylinders  
1164 representing the phospholipid bilayer was surrounded by a hollow elliptical cylinder  
1165 representing the two stacked MSP's. As usual<sup>69</sup> molecular constraints were  
1166 systematically implemented to constrain the solution space. As a part of this, the height  
1167 of the MSP was fixed to a value of 25.8 Å as derived from a high-resolution structure  
1168 of nanodiscs<sup>113</sup>. The scattering amplitudes of the hGHR-ECD-TMD and the GFP were  
1169 calculated from their atomic coordinates as a part of our *WillItFit*<sup>70</sup> framework and as  
1170 outlined in previous work<sup>37</sup> and incorporated into the ND rigid bodies. PDB 1EMA was  
1171 used for the GFP atomic coordinates while those of the flexible hGHR-ECD-TMD were  
1172 represented by a single of the structures obtained from the modelling of the ECD-TMD  
1173 linker with the N-terminal tail added from the ensemble produced in the modeling of  
1174 the full-length hGHR-ECD as described in previous sections. This allowed the TMD  
1175 to displace lipids in the ND and for adjusting the excess scattering lengths of the lipid  
1176 embedded residues by considering their lipid environment rather than the solvent<sup>37</sup>. The  
1177 averaged form factor intensity for the hGHR-ICD was modeled as a Gaussian Random  
1178 Coil through the Debye function<sup>51</sup>. The averaged form factor amplitude for a Gaussian  
1179 random coil required for the cross-terms in the calculation of  $I(q)$  is given by the so-

1180 called Hammouda function<sup>114</sup> which is a function of the ensemble average  $R_g$  of the  
1181 coil. Hence, we used the same modelling principle as previously applied for polymer  
1182 modified micelles<sup>115</sup> to connect the hGHR-ICD to the nanodisc embedded TMD in the  
1183 model. Following a similar philosophy, the GFP was randomly oriented and located  
1184 within a certain allocated “confusion volume”. This way the model captures the  
1185 dynamically evolving position of the GFP with respect to the rest of the system. For the  
1186 modelling of the confusion volume we attempted to mimic the bowl-like distribution  
1187 of GFP below the bilayer as observed in the CG-MD simulation of hGHR in a lipid  
1188 bilayer (see Fig 6F), by placing the GFP randomly in a thick cylindrical shell below the  
1189 nanodisc (see Fig 6A, inner and outer shell radii equal to, respectively, 1 and 1.5 times  
1190 the  $R_g$  of hGHR-ICD). However, we found that the actual shape of the confusion  
1191 volume, whether it was bowl-shaped or simply spherical, only had a minor effect.  
1192  
1193

1194   **REFERENCES**

1195

- 1196   1.    Madsen, K., Friberg, U., Roos, P., Edén, S. & Isaksson, O. Growth hormone  
1197       stimulates the proliferation of cultured chondrocytes from rabbit ear and rat rib  
1198       growth cartilage. *Nature* **304**, 545–7 (2005).
- 1199   2.    Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V. & Efstratiadis, A. Roles of  
1200       growth hormone and insulin-like growth factor 1 in mouse postnatal growth.  
1201       *Dev. Biol.* **229**, 141–62 (2001).
- 1202   3.    Waters, M. J. & Brooks, A. J. Growth hormone receptor: Structure function  
1203       relationships. *Horm. Res. Paediatr.* **76**, 12–16 (2011).
- 1204   4.    Isaksson, O. G., Jansson, J. O. & Gause, I. A. Growth hormone stimulates  
1205       longitudinal bone growth directly. *Science* **216**, 1237–9 (1982).
- 1206   5.    Guler, H. P., Zapf, J., Scheiwiller, E. & Froesch, E. R. Recombinant human  
1207       insulin-like growth factor I stimulates growth and has distinct effects on organ  
1208       size in hypophysectomized rats. *Proc. Natl. Acad. Sci. U. S. A.* **85**, 4889–93  
1209       (1988).
- 1210   6.    Yakar, S. *et al.* Circulating levels of IGF-1 directly regulate bone growth and  
1211       density. *J. Clin. Invest.* **110**, 771–81 (2002).
- 1212   7.    Chhabra, Y. *et al.* A growth hormone receptor SNP promotes lung cancer by  
1213       impairment of SOCS2-mediated degradation. *Oncogene* **37**, 489–501 (2018).
- 1214   8.    Chanson, P. & Salenave, S. Acromegaly. *Orphanet J. Rare Dis.* **3**, 17 (2008).
- 1215   9.    Melmed, S. *et al.* Current status and future opportunities for controlling  
1216       acromegaly. *Pituitary* **5**, 185–96 (2002).
- 1217   10.   Duncan, E. & Wass, J. A. Investigation protocol: acromegaly and its  
1218       investigation. *Clin. Endocrinol.* **50**, 285–93 (1999).
- 1219   11.   Mullis, P. E. Genetics of isolated growth hormone deficiency. *J. Clin. Res.*  
1220       *Pediatr. Endocrinol.* **2**, 52–62 (2010).
- 1221   12.   Reh, C. S. & Geffner, M. E. Somatotropin in the treatment of growth hormone  
1222       deficiency and Turner syndrome in pediatric patients: A review. *Clin.*  
1223       *Pharmacol. Adv. Appl.* **2**, 111–122 (2010).
- 1224   13.   Shimatsu, A., Nagashima, M., Hashigaki, S., Ohki, N. & Chihara, K. Efficacy  
1225       and safety of monotherapy by pegvisomant, a growth hormone receptor  
1226       antagonist, in Japanese patients with acromegaly. *Endocr. J.* **63**, 337–47  
1227       (2016).

- 1228 14. Brooks, A. J., Dehkhoda, F. & Kragelund, B. B. Cytokine Receptors. in  
1229 *Principles of Endocrinology and Hormone Action* (eds. Belfiore, A. &  
1230 LeRoith, D.) 157–185 (Springer International Publishing, 2018).  
1231 doi:10.1007/978-3-319-44675-2\_8
- 1232 15. Seiffert, P. *et al.* Orchestration of signaling by structural disorder in class 1  
1233 cytokine receptors. *Cell Commun. Signal.* **resubmitted**, (2020).
- 1234 16. Haxholm, G. W. *et al.* Intrinsically disordered cytoplasmic domains of two  
1235 cytokine receptors mediate conserved interactions with membranes. *Biochem.*  
1236 *J.* **468**, 495–506 (2015).
- 1237 17. Waters, M. J. The growth hormone receptor. *Growth Horm. IGF Res.* **28**, 6–10  
1238 (2016).
- 1239 18. Liongue, C. & Ward, A. C. Evolution of Class I cytokine receptors. *BMC Evol.*  
1240 *Biol.* **7**, 120 (2007).
- 1241 19. Baumgartner, J. W., Wells, C. A., Chen, C. M. & Waters, M. J. The role of the  
1242 WSXWS equivalent motif in growth hormone receptor function. *J. Biol. Chem.*  
1243 **269**, 29094–101 (1994).
- 1244 20. van den Eijnden, M. J. M., Lahaye, L. L. & Strous, G. J. Disulfide bonds  
1245 determine growth hormone receptor folding, dimerisation and ligand binding.  
1246 *J. Cell Sci.* **119**, 3078–86 (2006).
- 1247 21. Olsen, J. G. & Kragelund, B. B. Who climbs the tryptophan ladder? On the  
1248 structure and function of the WSXWS motif in cytokine receptors and  
1249 thrombospondin repeats. *Cytokine Growth Factor Rev.* **25**, 337–341 (2014).
- 1250 22. de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and  
1251 extracellular domain of its receptor: crystal structure of the complex. *Science*  
1252 **255**, 306–12 (1992).
- 1253 23. Brooks, A. J. *et al.* Mechanism of activation of protein kinase JAK2 by the  
1254 growth hormone receptor. *Science* **344**, 1249783 (2014).
- 1255 24. Wilmes, S. *et al.* Mechanism of homodimeric cytokine receptor activation and  
1256 dysregulation by oncogenic mutations. *Science* **367**, 643–652 (2020).
- 1257 25. Brown, R. J. *et al.* Model for growth hormone receptor activation based on  
1258 subunit rotation within a receptor dimer. *Nat. Struct. Mol. Biol.* **12**, 814–821  
1259 (2005).
- 1260 26. Fuh, G. *et al.* Rational design of potent antagonists to the human growth  
1261 hormone receptor. *Science* **256**, 1677–80 (1992).



- 1262 27. Sundström, M. *et al.* Crystal structure of an antagonist mutant of human growth  
1263 hormone, G120R, in complex with its receptor at 2.9 Å resolution. *J. Biol.*  
1264 *Chem.* **271**, 32197–32203 (1996).
- 1265 28. Chantalat, L., Jones, N. D., Korber, F., Navaza, J. & Pavlovsky, A. G. THE  
1266 CRYSTAL-STRUCTURE OF WILD-TYPE GROWTH-HORMONE AT 2.5  
1267 ÅNGSTROM RESOLUTION. *Protein Pept.Lett.* **2**, 333–340 (1995).
- 1268 29. Bocharov, E. V. *et al.* Structural basis of the signal transduction via  
1269 transmembrane domain of the human growth hormone receptor. *Biochim.*  
1270 *Biophys. Acta - Gen. Subj.* **1862**, 1410–1420 (2018).
- 1271 30. Bugge, K. *et al.* A combined computational and structural model of the full-  
1272 length human prolactin receptor. *Nat. Commun.* **7**, 1–11 (2016).
- 1273 31. Carroni, M. & Saibil, H. R. Cryo electron microscopy to determine the  
1274 structure of macromolecular complexes. *Methods* **95**, 78–85 (2016).
- 1275 32. Kassem, N., Kassem, M. M., Pedersen, S. F., Pedersen, P. A. & Kragelund, B.  
1276 B. Yeast recombinant production of intact human membrane proteins with long  
1277 intrinsically disordered intracellular regions for structural studies. *Biochim.*  
1278 *Biophys. acta. Biomembr.* **1862**, 183272 (2020).
- 1279 33. Breyton, C. *et al.* Small angle neutron scattering for the study of solubilised  
1280 membrane proteins. *Eur. Phys. J. E. Soft Matter* **36**, 71 (2013).
- 1281 34. Svergun, D. I. & Koch, M. H. J. Reports on Progress in Physics Related  
1282 content Small-angle scattering studies of biological macromolecules in solution  
1283 Small-angle scattering studies of biological macromolecules in solution.  
1284 *Reports Prog. Phys.* 1735 (2003).
- 1285 35. Bayburt, T. H., Grinkova, Y. V. & Sligar, S. G. Self-Assembly of Discoidal  
1286 Phospholipid Bilayer Nanoparticles with Membrane Scaffold Proteins. *Nano*  
1287 *Lett.* **2**, 853–856 (2002).
- 1288 36. Skar-Gislinge, N. *et al.* Small-angle scattering determination of the shape and  
1289 localization of human cytochrome P450 embedded in a phospholipid nanodisc  
1290 environment. *Acta Crystallogr. D. Biol. Crystallogr.* **71**, 2412–21 (2015).
- 1291 37. Kynde, S. A. R. *et al.* Small-angle scattering gives direct structural information  
1292 about a membrane protein inside a lipid environment. *Acta Crystallogr. Sect. D*  
1293 *Biol. Crystallogr.* **70**, 371–383 (2014).
- 1294 38. Bugge, K., Lindorff-Larsen, K. & Kragelund, B. B. Understanding single-pass  
1295 transmembrane receptor signaling from a structural viewpoint-what are we



- 1296 missing? *FEBS J.* **283**, 4424–4451 (2016).
- 1297 39. Dagil, R. *et al.* The WSXWS motif in cytokine receptors is a molecular switch  
1298 involved in receptor activation: Insight from structures of the prolactin  
1299 receptor. *Structure* **20**, 270–282 (2012).
- 1300 40. Glatter, O. A new method for the evaluation of small-angle scattering data. *J.*  
1301 *Appl. Crystallogr.* **10**, 415–421 (1977).
- 1302 41. Ahmed, M. C., Crehuet, R. & Lindorff-Larsen, K. Analyzing and comparing  
1303 the radius of gyration and hydrodynamic radius in conformational ensembles of  
1304 intrinsically disordered proteins. *bioRxiv* 679373 (2019). doi:10.1101/679373
- 1305 42. Bottaro, S., Bengtsen, T. & Lindorff-Larsen, K. Integrating Molecular  
1306 Simulation and Experimental Data: A Bayesian/Maximum Entropy  
1307 Reweighting Approach. *bioRxiv* 457952 (2018). doi:10.1101/457952
- 1308 43. Bugge, K., Steinocher, H., Brooks, A. J., Lindorff-Larsen, K. & Kragelund, B.  
1309 B. Exploiting hydrophobicity for efficient production of transmembrane helices  
1310 for structure determination by NMR spectroscopy. *Anal. Chem.* **87**, 9126–31  
1311 (2015).
- 1312 44. Shen, Y. & Bax, A. Identification of helix capping and b-turn motifs from  
1313 NMR chemical shifts. *J. Biomol. NMR* **52**, 211–32 (2012).
- 1314 45. Güntert, P. Automated NMR structure calculation with CYANA. *Methods Mol.*  
1315 *Biol.* **278**, 353–78 (2004).
- 1316 46. Khondker, A. *et al.* Membrane charge and lipid packing determine polymyxin-  
1317 induced membrane damage. *Commun. Biol.* **2**, 1–11 (2019).
- 1318 47. Bürck, J., Wadhwani, P., Fanghänel, S. & Ulrich, A. S. Oriented Circular  
1319 Dichroism: A Method to Characterize Membrane-Active Peptides in Oriented  
1320 Lipid Bilayers. *Acc. Chem. Res.* **49**, 184–92 (2016).
- 1321 48. Kassem, N., Kassem, M. M., Pedersen, S. F., Pedersen, P. A. & Kragelund, B.  
1322 B. Yeast recombinant production of intact human membrane proteins with long  
1323 intrinsically disordered intracellular regions for structural studies. *BBA -*  
1324 *Biomembr.* **1862** (6), 183272 (2019).
- 1325 49. Brown, W. & Mortensen, K. Comparison of Correlation Lengths in Semidilute  
1326 Polystyrene Solutions in Good Solvents by Quasi-Elastic Light Scattering and  
1327 Small-Angle Neutron Scattering. *Macromolecules* **21**, 420–425 (1988).
- 1328 50. Flory, P. J. *Principles of Polymer Chemistry*. Cornell University press (1953).
- 1329 51. Debye, P. Molecular-weight determination by light scattering. *J. Phys. Colloid*

- 1330 *Chem.* **51**, 18–32 (1947).
- 1331 52. Kohn, J. E. *et al.* Random-coil behavior and the dimensions of chemically  
1332 unfolded proteins. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 12491–6 (2004).
- 1333 53. Zheng, W. & Best, R. B. An Extended Guinier Analysis for Intrinsically  
1334 Disordered Proteins. *J. Mol. Biol.* **430**, 2540–2553 (2018).
- 1335 54. Riback, J. A. *et al.* Innovative scattering analysis shows that hydrophobic  
1336 disordered proteins are expanded in water. *Science* **358**, 238–241 (2017).
- 1337 55. Marsh, J. A. & Forman-kay, J. D. Sequence Determinants of Compaction in  
1338 Intrinsically Disordered Proteins. *Biophys J* **98**, 2383–2390 (2010).
- 1339 56. Stark, A. C., Andrews, C. T. & Elcock, A. H. Toward optimized potential  
1340 functions for protein-protein interactions in aqueous solutions: osmotic second  
1341 virial coefficient calculations using the MARTINI coarse-grained force field. *J.*  
1342 *Chem. Theory Comput.* **9**, 4176–4185 (2013).
- 1343 57. Javanainen, M., Martinez-Seara, H. & Vattulainen, I. Excessive aggregation of  
1344 membrane proteins in the Martini model. *PLoS One* **12**, e0187936 (2017).
- 1345 58. Larsen, A. H. *et al.* Combining molecular dynamics simulations with small-  
1346 angle X-ray and neutron scattering data to study multi-domain proteins in  
1347 solution. *PLoS Comput. Biol.* **16**, e1007870 (2020).
- 1348 59. Milkovic, N. M. *et al.* Interplay of folded domains and the disordered low-  
1349 complexity domain in mediating hnRNPA1 phase separation. *bioRxiv* (2020).  
1350 doi:10.1101/2020.05.15.096966
- 1351 60. Skar-Gislinge, N., Johansen, N. T., Høiberg-Nielsen, R. & Arleth, L.  
1352 Comprehensive Study of the Self-Assembly of Phospholipid Nanodiscs: What  
1353 Determines Their Shape and Stoichiometry? *Langmuir* **34**, 12569–12582  
1354 (2018).
- 1355 61. Johansen, N. T., Pedersen, M. C., Porcar, L., Martel, A. & Arleth, L.  
1356 Introducing SEC-SANS for studies of complex self-organized biological  
1357 systems. *Acta Crystallogr. Sect. D, Struct. Biol.* **74**, 1178–1191 (2018).
- 1358 62. Gent, J., van Kerkhof, P., Roza, M., Bu, G. & Strous, G. J. Ligand-independent  
1359 growth hormone receptor dimerization occurs in the endoplasmic reticulum and  
1360 is required for ubiquitin system-dependent endocytosis. *Proc. Natl. Acad. Sci.*  
1361 *U. S. A.* **99**, 9858–63 (2002).
- 1362 63. Rouser, G., Siakotos, A. N. & Fleischer, S. Quantitative analysis of  
1363 phospholipids by thin-layer chromatography and phosphorus analysis of spots.

- 1364 *Lipids* **1**, 85–6 (1966).
- 1365 64. Harding, P. A. *et al.* In vitro mutagenesis of growth hormone receptor Asn-  
1366 linked glycosylation sites. *Mol. Cell. Endocrinol.* **106**, 171–80 (1994).
- 1367 65. Bjørkskov, F. B. *et al.* Purification and functional comparison of nine human  
1368 Aquaporins produced in *Saccharomyces cerevisiae* for the purpose of  
1369 biophysical characterization. *Sci. Rep.* **7**, 1–21 (2017).
- 1370 66. Wennbo, H. *et al.* Activation of the prolactin receptor but not the growth  
1371 hormone receptor is important for induction of mammary tumors in transgenic  
1372 mice. *J. Clin. Invest.* **100**, 2744–51 (1997).
- 1373 67. Bernat, B., Sun, M., Dwyer, M., Feldkamp, M. & Kossiakoff, A. A. Dissecting  
1374 the binding energy epitope of a high-affinity variant of human growth  
1375 hormone: cooperative and additive effects from combining mutations from  
1376 independently selected phage display mutagenesis libraries. *Biochemistry* **43**,  
1377 6076–84 (2004).
- 1378 68. Kouadio, J.-L. K., Horn, J. R., Pal, G. & Kossiakoff, A. A. Shotgun alanine  
1379 scanning shows that growth hormone can bind productively to its receptor  
1380 through a drastically minimized interface. *J. Biol. Chem.* **280**, 25524–32  
1381 (2005).
- 1382 69. Skar-Gislinge, N. *et al.* Elliptical structure of phospholipid bilayer nanodiscs  
1383 encapsulated by scaffold proteins: casting the roles of the lipids and the protein.  
1384 *J. Am. Chem. Soc.* **132**, 13713–22 (2010).
- 1385 70. Pedersen, M. C., Arleth, L. & Mortensen, K. WillItFit : a framework for fitting  
1386 of constrained models to small-angle scattering data. *J. Appl. Crystallogr.* **46**,  
1387 1894–1898 (2013).
- 1388 71. Minezaki, Y., Homma, K. & Nishikawa, K. Intrinsically disordered regions of  
1389 human plasma membrane proteins preferentially occur in the cytoplasmic  
1390 segment. *J. Mol. Biol.* **368**, 902–13 (2007).
- 1391 72. Kjaergaard, M. & Kragelund, B. B. Functions of intrinsic disorder in  
1392 transmembrane proteins. *Cell. Mol. Life Sci.* **74**, 3205–3224 (2017).
- 1393 73. Ben-Avraham, D. *et al.* The GH receptor exon 3 deletion is a marker of male-  
1394 specific exceptional longevity associated with increased GH sensitivity and  
1395 taller stature. *Sci. Adv.* **3**, e1602025 (2017).
- 1396 74. Gouw, M. *et al.* The eukaryotic linear motif resource - 2018 update. *Nucleic*  
1397 *Acids Res.* **46**, D428–D434 (2018).

- 1398 75. Hamming, O. J. *et al.* Crystal structure of interleukin-21 receptor (IL-21R)  
1399 bound to IL-21 reveals that sugar chain interacting with WSXWS motif is  
1400 integral part of IL-21R. *J. Biol. Chem.* **287**, 9454–9460 (2012).
- 1401 76. Hofsteenge, J. *et al.* New Type of Linkage between a Carbohydrate and a  
1402 Protein: C-Glycosylation of a Specific Tryptophan Residue in Human RNase  
1403 Us. *Biochemistry* **33**, 13524–13530 (1994).
- 1404 77. Bürgi, J., Xue, B., Uversky, V. N. & van der Goot, F. G. Intrinsic Disorder in  
1405 Transmembrane Proteins: Roles in Signaling and Topology Prediction. *PLoS*  
1406 *One* **11**, e0158594 (2016).
- 1407 78. Kaplan, M. *et al.* EGFR Dynamics Change during Activation in Native  
1408 Membranes as Revealed by NMR. *Cell* **167**, 1241-1251.e11 (2016).
- 1409 79. Wang, X., Darus, C. J., Xu, B. C. & Kopchick, J. J. Identification of growth  
1410 hormone receptor (GHR) tyrosine residues required for GHR phosphorylation  
1411 and JAK2 and STAT5 activation. *Mol. Endocrinol.* **10**, 1249–60 (1996).
- 1412 80. Cormack, B. P. *et al.* Yeast-enhanced green fluorescent protein (yEGFP): A  
1413 reporter of gene expression in *Candida albicans*. *Microbiology* **143**, 303–311  
1414 (1997).
- 1415 81. Khondker, A., Malenfant, D. J., Dhaliwal, A. K. & Rheinstädter, M. C.  
1416 Carbapenems and Lipid Bilayers: Localization, Partitioning, and Energetics.  
1417 *ACS Infect. Dis.* **4**, 926–935 (2018).
- 1418 82. Himbert, S. *et al.* Hybrid Erythrocyte Liposomes: Functionalized Red Blood  
1419 Cell Membranes for Molecule Encapsulation. *Adv. Biosyst.* **4**, 1–11 (2020).
- 1420 83. Delaglio, F. *et al.* NMRPipe: A multidimensional spectral processing system  
1421 based on UNIX pipes. *J. Biomol. NMR* **6**, 277–293 (1995).
- 1422 84. Vranken, W. F. *et al.* The CCPN data model for NMR spectroscopy:  
1423 development of a software pipeline. *Proteins* **59**, 687–96 (2005).
- 1424 85. Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. TALOS+: a hybrid method  
1425 for predicting protein backbone torsion angles from NMR chemical shifts. *J.*  
1426 *Biomol. NMR* **44**, 213–23 (2009).
- 1427 86. Carper, W. R. Direct determination of quadrupolar and dipolar NMR  
1428 correlation times from spin - lattice and spin - spin relaxation rates. *Concepts*  
1429 *Magn. Reson.* **11**, 51–60 (1999).
- 1430 87. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25  
1431 years of image analysis. *Nat. Methods* **9**, 671–5 (2012).

- 1432 88. Jerabek-Willemsen, M. *et al.* MicroScale Thermophoresis: Interaction analysis  
1433 and beyond. *J. Mol. Struct.* **1077**, 101–113 (2014).
- 1434 89. Pedersen, P. A., Rasmussen, J. H. & Joergensen, P. L. Expression in high yield  
1435 of pig alpha 1 beta 1 Na,K-ATPase and inactive mutants D369N and D807N in  
1436 *Saccharomyces cerevisiae*. *J Biol Chem* **271**, 2514–2522 (1996).
- 1437 90. Blanchet, C. E. *et al.* Versatile sample environments and automation for  
1438 biological solution X-ray scattering experiments at the P12 beamline (PETRA  
1439 III, DESY). *J. Appl. Crystallogr.* **48**, 431–443 (2015).
- 1440 91. Petoukhov, M. V. *et al.* New developments in the ATSAS program package for  
1441 small-angle scattering data analysis. *J. Appl. Crystallogr.* **45**, 342–350 (2012).
- 1442 92. Jordan, A. *et al.* SEC-SANS: size exclusion chromatography combined in situ  
1443 with small-angle neutron scattering. *J. Appl. Crystallogr.* **49**, 2015–2020  
1444 (2016).
- 1445 93. Webb, B. & Sali, A. Protein Structure Modeling with MODELLER. in 1–15  
1446 (2014). doi:10.1007/978-1-4939-0366-5\_1
- 1447 94. Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory  
1448 research and analysis. *J. Comput. Chem.* **25**, 1605–12 (2004).
- 1449 95. Leaver-Fay, A. *et al.* ROSETTA3: an object-oriented software suite for the  
1450 simulation and design of macromolecules. *Methods Enzymol.* **487**, 545–74  
1451 (2011).
- 1452 96. Kleiger, G., Saha, A., Lewis, S., Kuhlman, B. & Deshaies, R. J. Rapid E2-E3  
1453 assembly and disassembly enable processive ubiquitylation of cullin-RING  
1454 ubiquitin ligase substrates. *Cell* **139**, 957–68 (2009).
- 1455 97. Zhang, J., Lewis, S. M., Kuhlman, B. & Lee, A. L. Supertertiary structure of  
1456 the MAGUK core from PSD-95. *Structure* **21**, 402–13 (2013).
- 1457 98. Koehler Leman, J. & Bonneau, R. A Novel Domain Assembly Routine for  
1458 Creating Full-Length Models of Membrane Proteins from Known Domain  
1459 Structures. *Biochemistry* **57**, 1939–1944 (2018).
- 1460 99. Alford, R. F. *et al.* An Integrated Framework Advancing Membrane Protein  
1461 Modeling and Design. *PLoS Comput. Biol.* **11**, e1004398 (2015).
- 1462 100. Qi, Y. *et al.* CHARMM-GUI Martini Maker for Coarse-Grained Simulations  
1463 with the Martini Force Field. *J. Chem. Theory Comput.* **11**, 4486–94 (2015).
- 1464 101. Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical  
1465 user interface for CHARMM. *J. Comput. Chem.* **29**, 1859–65 (2008).

- 1466 102. CG martini. Available at: [http://www.cgmartini.nl/index.php/force-field-](http://www.cgmartini.nl/index.php/force-field-parameters/particle-definitions)  
1467 parameters/particle-definitions.
- 1468 103. Abraham, M. J. *et al.* GROMACS: High performance molecular simulations  
1469 through multi-level parallelism from laptops to supercomputers. *SoftwareX* **1–**  
1470 **2**, 19–25 (2015).
- 1471 104. Marrink, S. J. & Tieleman, D. P. Perspective on the Martini model. *Chem. Soc.*  
1472 *Rev.* **42**, 6801–22 (2013).
- 1473 105. Alessandri, R. *et al.* Pitfalls of the Martini Model. *J. Chem. Theory Comput.*  
1474 **15**, 5448–5460 (2019).
- 1475 106. de Jong, D. H., Baoukina, S., Ingólfsson, H. I. & Marrink, S. J. Martini  
1476 straight: Boosting performance using a shorter cutoff and GPUs. *Comput. Phys.*  
1477 *Commun.* **199**, 1–7 (2016).
- 1478 107. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity  
1479 rescaling. *J. Chem. Phys.* **126**, 014101 (2007).
- 1480 108. Parrinello, M. & Rahman, A. Polymorphic transitions in single crystals: A new  
1481 molecular dynamics method. *J. Appl. Phys.* **52**, 7182–7190 (1981).
- 1482 109. Barducci, A., Bussi, G. & Parrinello, M. Well-tempered metadynamics: a  
1483 smoothly converging and tunable free-energy method. *Phys. Rev. Lett.* **100**,  
1484 020603 (2008).
- 1485 110. Granseth, E., Seppälä, S., Rapp, M., Daley, D. O. & Von Heijne, G. Membrane  
1486 protein structural biology - How far can the bugs take us? (Review). *Mol.*  
1487 *Membr. Biol.* **24**, 329–332 (2007).
- 1488 111. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. *J.*  
1489 *Mol. Graph.* **14**, 33–8, 27–8 (1996).
- 1490 112. Grudin, S., Garkavenko, M. & Kazennov, A. Pepsi-SAXS: an adaptive  
1491 method for rapid and accurate computation of small-angle X-ray scattering  
1492 profiles. *Acta Crystallogr. Sect. D, Struct. Biol.* **73**, 449–464 (2017).
- 1493 113. Bibow, S. *et al.* Solution structure of discoidal high-density lipoprotein  
1494 particles with a shortened apolipoprotein A-I. *Nat. Struct. Mol. Biol.* **24**, 187–  
1495 193 (2017).
- 1496 114. Hammouda, B. Structure factor for starburst dendrimers. *J. Polym. Sci. Part B*  
1497 *Polym. Phys.* **30**, 1387–1390 (1992).
- 1498 115. Pedersen, J. S. Form factors of block copolymer micelles with spherical,  
1499 ellipsoidal and cylindrical cores. *J. Appl. Crystallogr.* **33**, 637–640 (2000).



- 1500 116. Sonnhammer, E. L., von Heijne, G. & Krogh, A. A hidden Markov model for  
1501 predicting transmembrane helices in protein sequences. *Proceedings. Int. Conf.*  
1502 *Intell. Syst. Mol. Biol.* **6**, 175–82 (1998).
- 1503 117. Käll, L., Krogh, A. & Sonnhammer, E. L. L. A combined transmembrane  
1504 topology and signal peptide prediction method. *J. Mol. Biol.* **338**, 1027–36  
1505 (2004).
- 1506 118. Käll, L., Krogh, A. & Sonnhammer, E. L. L. Advantages of combined  
1507 transmembrane topology and signal peptide prediction--the Phobius web  
1508 server. *Nucleic Acids Res.* **35**, W429-32 (2007).
- 1509 119. Jones, D. T. Improving the accuracy of transmembrane protein topology  
1510 prediction using evolutionary information. *Bioinformatics* **23**, 538–44 (2007).
- 1511 120. Eisenberg, D., Schwarz, E., Komaromy, M. & Wall, R. Analysis of membrane  
1512 and surface protein sequences with the hydrophobic moment plot. *J. Mol. Biol.*  
1513 **179**, 125–42 (1984).
- 1514 121. UniProt Consortium. UniProt: a hub for protein information. *Nucleic Acids*  
1515 *Res.* **43**, D204-12 (2015).
- 1516
- 1517